Β Cell Replacement Therapy: A Novel Application For Targeted Epigenetic Editing by Ou, Kristy
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2018
Β Cell Replacement Therapy: A Novel Application
For Targeted Epigenetic Editing
Kristy Ou
University of Pennsylvania, ou.kristy@gmail.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Genetics Commons, and the Molecular Biology Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3168
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Ou, Kristy, "Β Cell Replacement Therapy: A Novel Application For Targeted Epigenetic Editing" (2018). Publicly Accessible Penn
Dissertations. 3168.
https://repository.upenn.edu/edissertations/3168
Β Cell Replacement Therapy: A Novel Application For Targeted
Epigenetic Editing
Abstract
Pancreatic β cells are the exclusive source of insulin, which normalizes blood glucose levels under
hyperglycemic conditions. In 2015, over 252,000 deaths in the United States were contributed by diabetes, a
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insufficient insulin secretion, resulting in chronic hyperglycemia and increased risk for severe health
complications. Although severely diabetic patients can clinically manage their glucose levels with mealtime
delivery of insulin analogues, many still experience potentially life-threatening hypoglycemic episodes due to
erroneous insulin administration. Only β cell replacement therapy, through the transplantation of deceased
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pregnancy or early diabetes, may identify exploitable pro-proliferative targets. However - as in the case with
overexpressing ST5, an activator of the Ras/ERK/MAPK pathway - there are often challenges associated with
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imprinting disorder characterized by massive β cell expansion, can stimulate β cell proliferation in adult
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Imprinting Control Region 2 in a locus specific manner. This demonstrates for the first time that epigenetic
editing can be employed to promote β cell proliferation, which may one day provide additional sources of
transplantable β cells in the future.
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ABSTRACT 
 
β CELL REPLACEMENT THERAPY:  
A NOVEL APPLICATION FOR TARGETED EPIGENETIC EDITING 
 
Kristy Ou 
Klaus H. Kaestner 
 
 Pancreatic β cells are the exclusive source of insulin, which normalizes blood glucose 
levels under hyperglycemic conditions. In 2015, over 252,000 deaths in the United States were 
contributed by diabetes, a family of disorders directly linked to defects in the pancreatic β cells. β 
cell deficiency or dysfunction leads to insufficient insulin secretion, resulting in chronic 
hyperglycemia and increased risk for severe health complications. Although severely diabetic 
patients can clinically manage their glucose levels with mealtime delivery of insulin analogues, 
many still experience potentially life-threatening hypoglycemic episodes due to erroneous insulin 
administration. Only β cell replacement therapy, through the transplantation of deceased donor-
derived pancreatic islets, can maintain long-term glycemic control without hypoglycemic episodes.  
 While β cell replacement therapy is an extraordinary breakthrough for diabetes treatment, 
the scarcity of transplantable β cells prevents it from becoming a realistic therapeutic option. 
Generating transplantable β cells through expansion of pre-existing β cells remains challenging 
given that healthy, adult β cells are resistant to cell cycle entry. Elucidating pathways that promote 
β cell expansion in mouse models, such as during pregnancy or early diabetes, may identify 
exploitable pro-proliferative targets. However - as in the case with overexpressing ST5, an activator 
of the Ras/ERK/MAPK pathway - there are often challenges associated with dissecting the pro-
proliferative and anti-proliferative signals in the β cell. 
 Human genetic diseases distinguished by β cell hyperplasia can also allude to pro-
proliferative therapeutic targets. Indeed, mimicking the epimutation underlying Beckwith-
Wiedemann Syndrome, a congenital imprinting disorder characterized by massive β cell expansion, 
can stimulate β cell proliferation in adult human islets. In order to introduce the epimutation, a 
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transcription activator-like effector protein fused to the catalytic domain of TET1 (TALE-TET1 fusion 
protein) was engineered to target and demethylate the Imprinting Control Region 2 in a locus 
specific manner. This demonstrates for the first time that epigenetic editing can be employed to 
promote β cell proliferation, which may one day provide additional sources of transplantable β cells 
in the future.  
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β cells, the sole source of insulin  
 
 Although constituting a mere 1% of the pancreas (or 0.0008% of an average male) by 
weight (Grosso and Vacarro, 2010), pancreatic islets are essential for human survival by 
functioning as the master homeostatic regulator of blood glucose - the near-exclusive source of 
metabolic energy for the brain, eyes, and red blood cells (Berg et al., 2002; Bacha et al., 2010). 
While most organs can utilize fatty acids or ketone bodies as additional sources of metabolic fuel, 
the brain requires glucose to initiate cellular respiration and generate adenosine triphosphate 
(ATP), the molecular source of energy that is necessary for life. In a person weighing 70 kilograms, 
four grams of circulating blood glucose (enough to fill a teaspoon) are constantly made readily 
available to the entire body for metabolic use, the circulating level tightly regulated by pancreatic 
islets (Wasserman, 2009). Prolonged low blood glucose (hypoglycemia) results in impaired neural 
function leading to confusion, fatigue, and in severe cases, seizures and loss of consciousness. 
Prolonged high blood glucose (hyperglycemia) leads to damage to the nerves, kidneys, and 
vasculature.  
Pancreatic islets are organized into spherical clusters containing five distinct endocrine cell 
types: α cells, β cells, δ cells, PP cells, and ε cells. Approximately 1 million islets are interspersed 
throughout the adult human pancreas, a secretory organ compartmentalized into separate exocrine 
and endocrine glands (Grosso and Vacarro, 2010). The pancreatic islets form the endocrine gland 
of the pancreas; they are highly vascularized, allowing both the sensitive detection of real-time 
blood glucose levels and the secretion of hormones into the bloodstream which act on peripheral 
tissues to normalize non-optimal blood glucose concentrations. The scattered islets, connected 
with each other only by a network of capillary vessels, are nestled within separated lobules 
containing thousands of clusters of acinar cells. The acinar clusters are linked by the pancreatic 
ductal system, which ultimately drains into the duodenum. Together, the acinar and ductal tissue 
form the exocrine gland of the pancreas, secreting digestive enzymes to facilitate the breakdown 
of food in the small intestine. Thus, both the exocrine and endocrine pancreas play important roles 
in nutrient breakdown and absorption.  
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Pancreatic islets are intriguing due to their heterogeneous composition and diverse 
functions, and were accordingly labeled as “micro-organs” by Dr. Paul Lacy, who is celebrated for 
his significant contributions to islet biology and transplantation research (Misler, 2010). Each of the 
five different pancreatic islet endocrine cell types secrete a distinct hormone in response to different 
blood glucose concentrations, summarized in Table 1.1 (Da Silva Xavier, 2018). β cells and α cells, 
which comprise approximately 50% and 40% of the pancreatic islet in humans, respectively, play 
the most significant roles in glucose homeostasis (Brissova et al., 2005). β cells react to increased 
blood glucose levels by secreting insulin. An elevation in extracellular glucose concentration results 
in greater glucose flux through high-capacity facilitative glucose transporters at the plasma 
membrane of β cells. Increased intracellular glucose results in amplified glycolytic flux, of which the 
very first and rate-limiting step is catalyzed by glucokinase, the glucose sensor of the β cell. 
Increased glycolysis due to a rise in intracellular glucose substrate ultimately leads to heightened 
intracellular ATP/ADP ratio. The rise in ATP inhibits ATP-sensitive potassium (KATP) channels, 
causing membrane depolarization, activation of voltage-gated calcium channels, and the large 
influx of Ca2+ which triggers the exocytosis of insulin granules. Insulin corrects hyperglycemia by 
stimulating glucose uptake by the skeletal muscle and adipose tissue via the insulin-regulated 
translocation of GLUT4 glucose transporters from intracellular vesicles to the plasma membrane. 
The absorbed glucose is stored in a polysaccharide form as glycogen, later to be used for energy 
in times of fasting. Insulin also inhibits glucose production by the liver.   
 When blood glucose levels drop during hypoglycemia, alpha cells secrete glucagon, a 
hormone that acts primarily on the liver to stimulate the breakdown of glycogen stores into single 
glucose molecules through the glycogenolysis pathway. Additionally, glucagon stimulates 
gluconeogenesis, which synthesizes glucose from non-carbohydrate precursors such as glycerol 
and certain amino acids. The liver then secretes the glucose generated from both glycogenolysis 
and gluconeogenesis into the circulation to raise glucose levels back to normoglycemia.  
Disruption of pancreatic endocrine activity, especially in β cells, leads to mismanagement 
of glucose levels and metabolic disorders. Identifying strategies to preserve or replace functional β 
cells are critical for the treatment of millions of hyperglycemic patients worldwide.  
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Diabetes: complex diseases of the β cells 
 
Few human diseases surpass the economic burden and global impact of diabetes, a family 
of complex metabolic syndromes primarily defined by hyperglycemia and insufficient insulin action. 
The World Health Organization (WHO) classifies diabetes as one of the four priority 
noncommunicable diseases (the other three being cardiovascular disease, cancer, and chronic 
respiratory disease) that are collectively responsible for over 32 million deaths annually worldwide, 
many of which are preventable (Riley et al., 2017). As part of the WHO Noncommunicable Diseases 
Global Action Plan for 2013-2020, the United Nations aims to reduce the global impact of diabetes 
by “implement(ing) guidelines and protocols to improve diagnosis and management of diabetes; … 
address(ing) key gaps in the diabetes knowledge base; … [and] strengthen(ing) national capacity 
to collect, analyse and use representative data on the burden and trends of diabetes and its key 
risk factors.” These goals demonstrate the importance of treating diabetes, which, when left 
uncontrolled, can result in life-threatening health complications such as cardiovascular disease, 
stroke, kidney disease, lower extremity amputations, and severe vision impairment (CDC, 2017a).  
 Diabetes is a collective term describing 50 different subcategories of the disease, the 
majority of which have unclear pathophysiology and complex associations with other disorders 
(CDC, 2017a; Forlenza et al., 2018). However, most of these subcategories are directly linked to 
defects in the pancreatic β cells. Type I and Type II Diabetes, the two most common forms of 
diabetes that account for 5% and 90% of total diabetic cases (CDC, 2017b), respectively, are both 
associated with β cell deficiency and/or dysfunction. Type I Diabetes, which is more commonly 
diagnosed in children and young adults, is caused by the autoimmune destruction of nearly all β 
cells. This abolishes insulin secretion altogether. Although the pathogenesis of Type I Diabetes is 
unclear, several mechanistic and genome-wide association studies suggest that genetic and 
developmental defects in the β cells play a role in triggering autoimmunity against themselves 
(Eizirik et al., 2012; Kutlu et al., 2009; Wallace et al., 2010). Due to the absence of functional β 
cells, Type I diabetic patients rely on insulin analogue injections at meal times for the rest of their 
lives to prevent diabetic coma, ketoacidosis, and death (Karges et al., 2017).  
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On the contrary, Type II Diabetes initially develops from insulin resistance - a condition 
exacerbated by excess weight and lack of physical activity that results in decreased insulin 
sensitivity and signaling in the skeletal muscle and adipose tissues (Schenk et al., 2008; Unger et 
al., 2010). Over time, insulin resistance can manifest into prediabetes (blood glucose levels higher 
than normal, but not high enough to be considered diabetic) if it has not been addressed by weight 
loss, change in diet, or increased exercise. As of 2015, approximately 1 in 3 American adults are 
diagnosed with prediabetes, highlighting the enormous prevalence of Type II Diabetes risk (CDC, 
2017b). During the early phases of prediabetes, the pancreatic islets initially adapt by increasing 
insulin secretion to overcome insulin resistance (Chen et al., 2016; Ferrannini et al., 2003). 
Overtime, glucolipotoxicity, oxidative stress, and endoplasmic reticulum stress progressivley 
contribute to de-differentiation or apoptosis of β cells (Prentki, 2006). The decline of functional β 
cells and insulin secretion leads to hyperglycemia and Type II Diabetes development (Deng et al., 
2004; Polonsky et al., 1996). Some patients are capable of treating their Type II Diabetes with 
metformin, which improves sensitivity to insulin (Pernicova and Korbonits, 2014), or sulfonylureas, 
which blocks KATP channels on β cells to depolarize the membrane and secrete more insulin 
(Panten et al., 1996). However, many rely on insulin therapy to correct their glucose levels 
(Moghissi and King, 2014; Panten et al., 1996; Sorli, 2014). 
 The significance of β cell dysfunction during diabetes pathogenesis is highlighted in the 
other rarer forms of diabetes. There are ten autosomal dominant monogenic forms of diabetes that 
are caused by a mutations in genes encoding for transcription factors or proteins critical for insulin 
synthesis or secretion (Table 1.2) (Sperling and Garg, 2018). These mutations result in maturity-
onset diabetes of the young (MODY1-10), which constitutes 2% of total diabetic cases. MODY3, 
the most common form of MODY, is caused by dominant-negative mutations in hepatic nuclear 
factor 1-alpha (HNF1A), a transcription factor necessary for liver and β cell function. In vitro and in 
vivo studies have demonstrated that HNF1A transcriptionally regulates genes important for 
glucose-stimulated insulin secretion (Wang, 2000); (Ekholm et al., 2011; Pontoglio et al., 1998). 
MODY3 patients are initially responsive to treatment with sulfonylureas which promotes greater 
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insulin secretion in β cells. However, many require insulin therapy later in life due to progressive 
deterioration of β cells.  
 
Finding a cure for diabetes 
 Patients with severe forms of diabetes are treated successfully with insulin therapy. 
Nevertheless, they experience health challenges and unmet medical needs. Mealtime insulin 
administration requires accurate estimation of carbohydrate consumption while simultaneously 
taking into consideration the timing of insulin action and changes in insulin sensitivity depending 
on recent physical activity or illness (Sorli and Heile, 2014). Administering insulin at too high of a 
dose can lead to hypoglycemia, which may require hospitalization depending on the severity of the 
episode. One in three type I diabetic patients report experiencing a severe episode of hypoglycemia 
at least once a year (Weinstock et al., 2013) - a concerning proportion given that insulin therapy is 
currently considered the most effective treatment for severe diabetes.  
 Conversely, administering insufficient insulin can fail to achieve desired glycemic control. 
Persistent hyperglycemia in diabetic patients result in increased risk for cardiovascular, renal, and 
neural damage. Because of these challenges, there remains an urgent demand for new therapies, 
particularly those that can control extreme glucose excursions.  
 Major advancements in purifying human islets from pancreata obtained from deceased 
organ donors have allowed for human islet transplantation clinical trials to take place (Bertuzzi and 
De Carlis, 2016; Ricordi et al., 2016). In 2004, the National Institutes of Health (NIH) established 
the Clinical Islet Transplantation (CIT) Consortium to both standardize isolation of clinical grade 
pancreatic islet across multiple manufacturing centers and determine the safety and efficacy of islet 
transplantation in type I diabetic patients. To date, over 1000 patients with Type I Diabetes have 
received islet transplantations (Shapiro, 2012). The results of the most recent multicenter Phase III 
clinical trial demonstrated that transplantation of human islets eliminated severe hypoglycemia 
episodes in all subjects, and that 87.5% of subjects were capable of maintaining normal or near-
normal glycemic control a year after the transplant (Hering et al., 2016). Since the conception of 
the Edmonton protocol, 60% of total CIT Consortium-treated patients have remained insulin 
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independent for at least 5 years (Shapiro et al., 2017). These results are extraordinary given that 
patients with Type I Diabetes are otherwise completely reliant on injections of insulin multiple times 
a day, and will likely lead to U.S. Food and Drug Administration (FDA) approval of islet 
transplantation as a therapy for type I diabetic patients.  
 
Human islet transplantation 
The manufacturing process human pancreatic islets involves many fastidious steps from 
organ procurement to purification to safety assessment. After verifying that a pancreas has met all 
donor inclusion criteria, the manufacturing center begins the islet isolation procedure by disinfecting 
the the organ in a sterilization buffer containing an antibiotic or antiseptic (Ricordi et al., 2016). The 
disinfected pancreas is then separated into two pieces (head and body/tail sections) to allow for 
perfusion of a collagenase enzyme solution for several minutes via a cannula inserted into the 
pancreatic duct. The perfused pancreas is then divided into 5-15 smaller pieces and placed into a 
“Ricordi” digestion chamber, which mechanically shears apart the fibrous connective tissue 
encasing the thousands of acinar lobules, releasing the pancreatic islets into a dilution buffer (Gray 
et al., 2004). The collected pancreatic islets are then purified through multiple density gradient 
centrifugation steps and assessed for percentage of purity by dithizone (DTZ) staining (Ricordi et 
al., 1990). DTZ is a zinc-chelating agent that appears bright red when bound to free zinc ions 
(Wijesekara et al., 2009). Pancreatic β cells are rich in zinc, an essential cofactor for the processing, 
packaging, and secretion of insulin, and are thus strongly labeled by DTZ, while acinar and other 
cell types are not. The purified islets are cultured for 36 - 72 hours prior to final quality and safety 
assessments for endotoxin and microbial presence.  
After the quality control steps, the purified islets are collected into a transplant infusion bag 
and transplanted into a Type I diabetic registered subject within six hours (McCall and Shapiro, 
2012). The donor islets are infused into the recipient's portal vein, a major vessel that supplies 
blood to the liver from the gastrointestinal system. The islets settle into smaller venules, allowing 
for immediate glucose detection after a meal, and insulin secretion into the circulation.  
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Expanding sources of β cells for replacement therapy 
 
Although islet transplantation represents a breakthrough for treating Type I Diabetes and 
other severe forms of insulin-dependent diabetes, it is unlikely to become a routine standard of care 
therapy within the near future unless several clinical challenges are overcome. Like with all other 
cellular and organ transplantation therapies, complications frequently arise from 
immunosuppression regimens that cause serious risk for infection at the cost of preventing 
transplant rejection (McCall and Shapiro, 2012).  
 Furthermore, the scarcity of donors prevents islet transplantation from becoming a feasible 
treatment option for the vast majority of type I diabetic patients. In 2017, there were 1,316 pancreata 
recovered from registered deceased donors in the United States (U.S. Department of Health and 
Human Services). This number is drastically reduced after eliminating organs that do not meet the 
inclusion and exclusion criteria (i.e.- no history of diabetes, did not die from cardiac arrest, etc) 
(Ricordi et al., 2016). Because of the very limited number of donor pancreata available for islet 
purification, identifying strategies to procure additional sources of insulin-secreting β cells for 
cellular replacement therapy, or to regenerate depleted β cell mass in vivo, is arguably the most 
important goal for the diabetes research community.  
 
β cell replacement by reprogramming   
Over the past decade, protocols for the differentiation of human embryonic stem cells 
(hESCs) into β-like cells have significantly improved (Rattananinsruang et al., 2018; Van Hoof et 
al., 2009). Human ESCs are an attractive source of β cells because they maintain pluripotency 
throughout cell division through self-renewal processes; theoretically, an indefinite number of β-like 
cells can be differentiated from this continual pool of hESCs. In order to derive insulin-producing 
cells, pluripotent hESCs are first differentiated stepwise through the four stages of pancreatic 
development via specific culture conditions defined by the cocktail of signaling molecules and 
growth factors (Rezania et al., 2012). They are first differentiated into the “definitive endoderm,” 
which takes three days under the presence of activin-A and Wnt3A at different concentrations on 
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different days. Next, the hESC-derived “definitive endoderm” cells are treated with FGF7 to produce 
the “primitive gut tube.” After three days, they are next differentiated into the “posterior foregut” 
through the treatment of SANT-1, retinoic acid, Noggin, and B27 for four days. 
Finally, the pancreatic endoderm is derived after four days of treatment with ALK5 inhibitor, 
Noggin, TPB, and B27, which drives the expression of transcription factors PDX1. PDX1 is 
necessary for pancreatic cell fate commitment, and its absence prevents pancreatic endocrine and 
acinar development in mouse ablation studies (Gao et al., 2008; Offield et al., 1996). However, the 
commitment of the hESC-derived pancreatic endoderm to endocrine precursor cells has proven to 
be challenging. Developmental studies in mice describe transient and biphasic expression of 
endocrine progenitor transcription factor Neurogenin-3 (Ngn3), which has been difficult to 
recapitulate in vitro (Gradwohl et al., 2000; Gu et al., 2002). Furthermore, the final step to generate 
a differentiated β-like cell, which requires the activation of β cell maturation transcription factors 
MAFA, NKX6.1, and PDX1, is imperfect. The final differentiated product contains a significant 
number of immature, bi-hormonal insulin- and glucagon-expressing cells that are unable to respond 
to glucose stimuli appropriately. This limitation may stem from incomplete knowledge of the 
transcriptional program necessary to drive the in vitro differentiation of pancreatic endoderm into β 
cells. 
  In 2008, several studies demonstrated that hESC-derived pancreatic endoderm is a 
transplantable source of glucose-sensing, insulin-secreting cells in a rodent model (Kroon et al., 
2008). Transplanting hESC-derived pancreatic endoderm into immunodeficient mice generated β 
cell precursors that spontaneously matured into functional β-like cells, presumably because the 
precursors are exposed to circulating differentiation factors necessary for β cell lineage 
specification.  In 2014, the regenerative medicine biotechnology company ViaCyte initiated a 
Phase I/II study to determine the safety and efficacy of treating Type I Diabetes with the world’s 
first hESC-derived β cell replacement therapy: investigational product VC-02, an implantable 
capsule containing pancreatic endoderm cells derived from hESCs (Agulnick et al., 2015; Schulz 
et al., 2012).  
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Other studies have demonstrated the feasibility of directly reprogramming other pancreatic 
cell types, such as alpha cells, into β cells. This strategy is particularly appealing because alpha 
cells originate from the same endocrine progenitor cell as the β cell, and contain bivalent H3K4me3-
activating and H3K27me3-repressive epigenetic modifications at promoters of β-cell specific genes 
(Bramswig et al., 2013). Other studies have also reported the intrinsic epigenomic plasticity of alpha 
cells - especially in the context of β cell loss during diabetes pathogenesis - incentivizing the 
transdifferentiation of alpha cells to generate additional β cell mass (Chakravarthy et al., 2017). 
Recently, a study displayed efficient conversion of both mouse and human alpha cells into β cells 
by using viral gene therapy to overexpress the β cell-specific transcription factors Pdx1 and MafA 
(Xiao et al., 2018). These reprogrammed former alpha cells were glucose sensitive and able to 
correct for hyperglycemia in two different mouse models of diabetes.  Similar reprogramming 
studies in mouse pancreatic ductal cells and hepatocytes also report successful conversion of non-
β cell types into functional insulin-secreting cells (Chang et al., 2016; Wang et al., 2018).  
 
β cell replacement by inducing proliferation 
 Although hESC and non-β cell reprogramming are promising strategies to regenerate 
sources of β cells, perhaps the most relatively straightforward approach is to induce proliferation in 
pre-existing β cells. β cells are capable of compensating for increased insulin demand during insulin 
resistance and pregnancy by expanding through mechanisms regulating cell proliferation, at least 
in rodents (Baeyens et al., 2016; Linnemann et al., 2014). Furthermore, recent small molecule 
screenings have identified compounds such as harmine and 5-iodotubercidin that induce human β 
cell proliferation in vitro and in vivo, and have protected mice from diet- and streptozotocin-induced 
hyperglycemia (Dirice et al., 2016; Wang et al., 2015a). Although these findings are encouraging, 
only a small percentage of β cells respond to small molecule treatments. Adult β cells are resistant 
to cell cycle entry and remain relatively quiescent for the entirety of their lifespan (Wang et al., 
2015b). In order to boost replication in a greater proportion of β cells and expand sources for cell 
replacement therapy, it is critical to understand the mechanisms that regulate and restrict 
proliferation in β cells. Examining pathways that control cell cycle progression have revealed 
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interesting disparities between young and old cells, as well as differences between quiescent and 
metabolically stressed β cells. 
 
The cell cycle in β cells  
 
 The four stages of the cell cycle - G1, S, G2, and M - are tightly coordinated by cyclins, 
cyclin-dependent kinases (CDKs), and cyclin-dependent kinase inhibitors (CDKNs). Different 
classes of cyclins are cyclically expressed and degraded at the start and end of each cell cycle 
phase. Members of the cyclin family of regulatory proteins can be categorized into four different 
classes, depending on when they are the most expressed and active: The G1 class Cyclin D 
facilitates commitment to cell cycle progression, exit of G1 checkpoint phase, and entry into G1/S 
phase transition; the G1/S class Cyclin E prepares the cell for upcoming S phase and DNA 
synthesis; the S class Cyclin A initiates and completes DNA synthesis, and regulates G2 checkpoint 
phase; and M class Cyclin B initiates and completes mitotic division (Asghar et al., 2015). Although 
every cyclin has a unique protein structure and function, they each contain a conserved 100 amino 
acid motif defined as the cyclin box. Cyclins bind to and activate kinase activity of their target cyclin-
dependent kinase (CDK) partners through this motif. Notably, protein levels of cyclins oscillate 
throughout different phases of the cell cycle, but CDK levels remain relatively constant (Asghar et 
al., 2015). The heterodimerization of the cyclin and its CDK partner leads to phosphorylation and 
activation of pro-proliferative proteins. For example, upregulation of Cyclin D via growth factor-
mediated signaling leads to the formation of Cyclin D-CDK4 and Cyclin D-CDK6 complexes. 
Activated CDK4/6 phosphorylates and inactivates retinoblastoma protein (Rb), disinhibiting 
members of the E2F cell cycle activator family (E2F1, E2F2, E2F3a) (Yang, 2012). Free E2F 
upregulates downstream transcriptional targets, such as DNA replication machinery genes, that 
are necessary for the G1/S phase transition. 
Cyclin-dependent kinase inhibitors (CDKN) inhibit cell proliferation by forming stable 
complexes with target CDKs to prevent cyclin-dependent activation. There are two classes of 
CDKNs (Quereda et al., 2016). The INK4 family of inhibitors (CDKN2A or p16, CDKN2B/p15, 
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CDKN2C/p18, CDKN2D/p19) bind to and inhibit CDK4/6, preventing Rb phosphorylation and G1/S 
phase transition. In contrast, the CIP/KIP family of inhibitors (CDKN1A/p21, CDKN1B/p27, and 
CDKN1C/p57) has been shown to interact with and disrupt all Cyclin-CDK complexes at every cell 
cycle phase. Both CDKN families play a prominent role in β cell quiescence (Fiaschi-Taesch et al., 
2013). 
β cells exhibit their highest rate of replication during early postnatal development in both 
humans and mice (Figure 1.1) (Meier et al., 2008; Wang et al., 2016a). Histological and mass 
cytometry analyses indicate that approximately 2 - 4% of human β cells are positive for the 
proliferation marker Ki-67 in samples obtained from deceased postnatal donors aged 2 to 12 
months old. The percentage of Ki-67 positive β cells dramatically diminishes to 0.5 - 1% within the 
first 10 years of life and continuously declines with age. The near absence of proliferation in adult 
β cells is emphasized by a recent study that did not find a single proliferating β cell (as assessed 
by Ki-67 staining) after counting a total of 37,845 β cells among 18 adult pancreata samples (Mezza 
et al., 2013). 
 Studies in mice have identified several factors necessary for β cell proliferation during 
postnatal development. Immunocytochemistry staining of neonatal pancreata in Cyclin D2 null mice 
(Cyclin D2-/-) and wild-type controls revealed that Cyclin D2 is necessary for postnatal β cell 
replication (Georgia and Bhushan, 2004). Deletion of Cyclin D2 had no impact on embryonic β cell 
proliferation as the size and mass of neonatal islets were identical between controls and mutants. 
However, 14 day old Cyclin D2-/- mice displayed dramatically smaller islet size, a 4-fold reduction 
in β cell mass, and blunted insulin secretion that correlated with impaired glucose tolerance. 
Likewise, Cdk4 null mice (Cdk4-/-) had disrupted postnatal β cell proliferation that resulted in 
decreased β cell mass, insulin deficiency, and diabetes development in adult mice (Mettus and 
Rane, 2003).  
The forkhead box M1 (FoxM1) transcription factor is also necessary for postnatal β cell 
proliferation (Mettus and Rane, 2003; Zhang et al., 2006). Inactivation of FoxM1 during early 
pancreatic development using a Pdx1-Cre transgenic line crossed with FoxM1fl/fl mice (FoxM1Δpanc) 
did not affect β cell mass during embryonic and fetal development. However, as neonatal 
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FoxM1Δpanc mice aged, they displayed progressively reduced islet size and β cell mass, resulting in 
diabetes. This finding is consistent with other studies that demonstrate FoxM1 transcriptionally 
activates G1/S and G2/M transition genes in other cell types (Krupczak-Hollis et al., 2004; Wang 
et al., 2002).  
 
A change with age   
The progressive age-associated decline in the proliferative capacity of β cells can largely 
be attributed to transcriptional and epigenetic changes (Avrahami et al., 2015; Rankin and Kushner, 
2010). Adult β cells express significantly reduced levels of cyclins and FoxM1 while simultaneously 
upregulating p16 (Krishnamurthy et al., 2006). The accumulation of p16 inhibits the kinase activity 
of Cdk4 and Cdk6, prohibiting the phosphorylation and inactivation of retinoblastoma protein (Rb). 
In its unphosphorylated state, Rb sequesters the transcriptional activator domain of the E2F cell 
cycle activator family; the resulting Rb-E2F complex prevents transcriptional activation of 
downstream pro-proliferative E2F targets. The strong anti-proliferative effect of p16 on adult β cells 
was demonstrated through several in vivo studies. Young transgenic mice overexpressing p16 
displayed a significant decrease in the percentage of proliferating β cells identified by Ki-67 
immunostaining when compared to wild-type littermate controls (Krishnamurthy et al., 2006). 
Conversely, the percentage of Ki-67+ β cells doubled in adult p16 null mice (p16-/-), which were 
prone to developing tumors, relative to the wild-type control. Additionally, adult p16-/- mice were 
able to regenerate β cell mass and normalize blood glucose levels in response to streptozotocin-
induced β cell damage faster than control animals (Krishnamurthy et al., 2006).  
 
Aging and DNA methylation 
The mechanisms responsible for the upregulation of p16 and downregulation of pro-
proliferative genes are poorly understood, though it is becoming more evident that changes in the 
epigenetic profile of juvenile and adult β cells underlie these age-related transcriptional differences. 
The most well characterized epigenetic modification is DNA methylation, a covalent biochemical 
modification found predominantly on cytosines adjacent to guanines (CpG). Since its discovery in 
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the 1940’s, several regulatory functions have been linked to DNA methylation: transcriptional 
silencing of genes, genomic imprinting of monoallelically expressed genes, repression of unstable 
transposable elements, and inactivation of the second X chromosome in female mammals (Smith 
and Meissner, 2013). An estimated 80% of all CpGs are sparsely interspersed throughout the entire 
genome and are methylated (Schrader et al., 2015). Strikingly, less than 10% of all CpGs are 
located in CG-dense regions, termed CpG islands, that are frequently found at promoters of genes; 
there is little to no methylation at the vast majority of CpG islands (Deaton and Bird, 2011). 
Daughter cells of a dividing parent cell will inherit the genome-wide methylation signature 
in addition to the duplicated chromosomes. The heritable pattern of DNA methylation is attributed 
by two factors: the inherent palindromic nature of CpGs, and the activity of DNA-methyltransferase 
1 (DNMT1) during DNA synthesis in S phase (Hervouet et al., 2012). If methylation is present on a 
CpG located at a specific genomic coordinate on the sense (+) strand of double-stranded DNA, it 
is also present on the opposite antisense (-) strand due to Watson-Crick base pairing of cytosines 
to guanines, resolving as a CpG at the identical location on the antisense strand. Mechanistically, 
nascent unmethylated strands of DNA are synthesized from the methylated template during the S 
phase of the cell cycle, resulting in hemi-methylated sister chromatids. During DNA synthesis, 
DNMT1 recognizes hemi-methylated CpGs and re-establishes the methylation signature on the 
nascent DNA strand, thus providing maintenance of the DNA methylation profile through indefinite 
cycles of cell divisions. Because of this phenomenon, DNA methylation serves as a source of 
memory for the daughter cells’ previous identity pre-mitosis - a crucial feature that has been 
implicated in restricting developmental cell fate determination and maintaining identity after cell 
division (Smith and Meissner, 2013).  
Yet despite the stable and heritable nature of DNA methylation, there can be global and 
local changes to the methylation profile over time. De novo methylation, catalyzed by the DNA 
methyltransferases DNMT3A and DNMT3B, can occur at CpGs that were formerly unmethylated 
(Reik et al., 1999). Furthermore, DNA demethylation can occur passively over the course of multiple 
cell divisions through unfaithful maintenance by DNMT1, or in targeted fashion through the 
oxidation of methyl-cytosines (5-mC) into hydroxymethyl-cytosines (5-hmC) by the ten eleven 
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translocation (TET) family of methylcytosine dioxygenases. Because DNMT1 methyltransferases 
do not recognize 5-hmC as a substrate, the methylated cytosine is lost in post-mitotic daughter 
cells. The TET enzymes are also capable of catalyzing stepwise oxidation of 5-hmC into 
formylcytosine (5-fC) and carboxylcytosine (5-caC). Both 5-fC and 5-caC can be excised and 
replaced with an unmodified cytosine by thymine DNA glycosylase (TDG)-mediated base excision 
repair (Wu and Zhang, 2017). Aberrant regulation of factors involved with DNMT or TET recruitment 
can lead to a disruption in the DNA methylation landscape, a hallmark of aging and disease 
pathogenesis. The decreased proliferative capacity of aging β cells and the ensuing risk for 
diabetes are no exceptions.  
 In a recent study that profiled the transcriptomes and methylomes of juvenile and aged 
mouse β cells, significant de novo methylation was discovered at the promoters and enhancers of 
pro-proliferative cell cycle genes (Avrahami et al., 2015). The increase in methylation was 
correlated with transcriptional silencing at these genes, suggesting a mechanism for the age-
associated decline in β cell proliferation. Furthermore, aging is correlated with decreased 
expression of Enhancer of zeste homolog 2 (Ezh2), a component of the Polycomb Repressive 
Complex 2 (PRC2) that transcriptionally silences chromatin through trimethylation of histone H3 on 
lysine 27 (H3K27me3) (Chen et al., 2009). Decreased levels of Ezh2 are linked to de-repression of 
the Cdkn2a/p16 locus in aged β cells. Increased transcriptional activity of the Cdkn2a/p16 locus is 
also attributed to the age-associated decline in levels of Polycomb Repressive Complex 1-
associated protein, Bmi-1 (Dhawan et al., 2009). Decreased Bmi-1 resulted in the loss of repressive 
histone H2A ubiquitylation, promoting methylation at lysine 4 of histone H3 (H3K4) and 
transcriptional activation of Cdkn2a/p16.  
While the mechanisms underlying the observed epigenetic and transcriptional changes in 
aging β cells are largely unclear, identifying strategies to “rejuvenate” adult β cells into a younger 
state may provide answers for expanding β cell mass.  
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Physiological adaptive β cell proliferation 
 
 While adult β cells are largely resistant towards cell cycle entry and proliferation, there are 
specific conditions that induce β cell proliferation in order to compensate for the increase in insulin 
demand, at least in rodents. Examining the mechanisms behind the adaptive proliferative response 
of β cells under metabolic stress - namely during pregnancy and obesity - have identified mitogenic 
pathways that can be potentially activated in dormant β cells.  
 
Pathways regulating β cell proliferation during pregnancy  
Female mammals undergo a metabolic transformation during pregnancy in order to supply 
essential nutrients to the developing fetus. In particular, gestational glucose metabolism is marked 
by distinct, dynamic phases that are coordinated with the stage of pregnancy (Angueira et al., 
2015). During early placental and embryonic development, an increase in vasculature and total 
blood volume (among other factors) results in a decrease of circulating blood glucose levels and a 
subsequent enhancement of insulin sensitivity. As pregnancy progresses throughout the second 
and third trimesters, available glucose is redirected to the growing fetus by an elevated secretion 
of the placental-derived hormones placental lactogen (hPL) and placental growth hormone (GH-
V), as well as maternally derived cortisol, leptin, and progesterone (Murr et al., 1974; Ryan and 
Enns, 1988). All of these hormones promote insulin resistance and impair glucose absorption by 
the mother’s peripheral organs, redirecting available glucose to the growing fetus.  
In order to compensate for blunted insulin receptor signaling, the mother’s β cells increase 
production of insulin by proliferating and expanding sources of insulin. Failure to proliferate results 
in gestational diabetes onset (Devlieger et al., 2008). Studies in rodents indicate that a significant 
proportion of β cells undergo proliferation, where peak proliferation correlates with greatest insulin 
secretion. In pregnant mice, there is a progressive increase in β cell proliferation, quantified by 
BrdU incorporation, which peaks at gestational day 15 (GD 15) (Karnik et al., 2007). During this 
time, the rate of proliferating β cells is increased by 5-fold, peaking at 2.5% (compared to 0.5% 
before pregnancy), and total β cell mass is expanded by 75%.  
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Several mitogenic pathways are upregulated during pregnancy due to the presence of 
growth factors and hormones. Placental lactogen, which has an established role in gestational β 
cell mass expansion in addition to gestational insulin resistance, activates the Jak2/Stat5 signaling 
pathway downstream of the prolactin tyrosine kinase receptor in β cells, resulting in the dimerization 
and nuclear translocation of the transcriptional activator Stat5 (Ernst et al., 2011; Hakonen et al., 
2014). Downstream targets of Stat5 include FoxM1 (previously mentioned to play a role in postnatal 
β cell proliferation) and Bcl6, a transcriptional repressor.  
Activation of Bcl6 through placental lactogen receptor signaling represses expression of 
menin (Men1), a tumor suppressor protein that is a component of the MLL/SET1 methyltransferase 
complex which specifically methylates H3K4, promoting gene activation (Karnik et al., 2007; Tran 
et al., 2010). Men1 promotes expression of cell cycle inhibitors p27 and p18 through histone H3K4 
methylation, and thus the progressive decline in Men1 during pregnancy is accompanied by 
reduced expression of p27 and p18 (Karnik et al., 2007). Protein levels of Men1, p27, and p18 are 
all significantly anticorrelated with the percentage of proliferating β cells during pregnancy. 
Conditional overexpression of Men1 in β cells (βMen1) prevented pregnancy-induced 
downregulation of p27 and p18 levels compared with non-pregnant controls. This resulted in 
attenuated β cell proliferation, leading to significantly impaired glucose tolerance compared to 
control pregnant mice when assessed at GD 15 (during which β cell proliferation normally peaks) 
(Karnik et al., 2007). There were no differences between insulin content and secretion between 
islets isolated from pregnant βMen1 and control mice, suggesting that impaired glucose tolerance 
in Men1-overexpressing mice is contributed by the absence of β cell expansion and not defects in 
β cell functionality.  
 Signaling through the epidermal growth factor receptor (EGFR), another receptor tyrosine 
kinase, has also been shown to play a pivotal role in gestational β cell expansion. Pregnant female 
mice expressing a dominant negative, kinase-deficient human EGFR mutant under the β cell 
specific Pdx1 promoter (EGFR-DN), experience gestational diabetes that is not present in pregnant 
wild-type mice at gestational day 13.5 (GD 13.5) (Hakonen et al., 2011). This observation correlated 
with attenuated β cell proliferation, as detected by Ki-67 staining, and failure to expand total β cell 
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mass. Non-pregnant EGFR-DN females had normal glucose tolerance, suggesting that EGFR 
signaling plays a critical role in β cell proliferation in response to gestational metabolic stress. 
Notable EGFR ligands that are upregulated during pregnancy include βcellulin (BTC) and heparin-
binding epidermal growth factor-like growth factor (HB-EGF), both of which have been shown to 
facilitate β cell proliferation in non-pregnant mice (Oh et al., 2011; Zarrouki et al., 2014). 
Additionally, the activated prolactin receptor can mediate phosphorylation and activation of the 
intracellular signaling domain of EGFR (Hakonen et al., 2014). Once activated, EGFR stimulates 
several signal transduction cascades that are important for β cell proliferation such as the 
PI3K/AKT/mTOR and the RAS/RAF/MEK/ERK (also known as the MAPK pathway) pathways.  
 
Pathways regulating β cell proliferation during obesity and early diabetes  
 Obesity is another potent stimulator of β cell proliferation, and failure in β cell adaptation 
leads to diabetes in rodents. Excessive lipid accumulation in the liver, skeletal muscle, and adipose 
tissues correlated with impaired insulin signaling, causing insulin resistance and hyperglycemia 
(Golson et al., 2010). Studies in different rodent models of obesity, including diet-induced obesity 
models and genetic models, have uncovered several pathways that regulate expansion of β cell 
mass via increased replication. The two most commonly used genetic models of obesity have 
disrupted leptin signaling, which has downstream effects on satiety, energy expenditure, and insulin 
action. Leptin is a hormone predominantly secreted by the adipose tissue and is best characterized 
by its function on the hypothalamus (Zhou and Rui, 2013). Binding of leptin to the leptin receptor at 
the surface of hypothalamic cells results in receptor dimerization and activation of the receptor-
associated Jak2 tyrosine kinase, which in turn phosphorylates and activates Stat3 and Stat5. 
Phosphorylated Stat3 and Stat5 homodimerizes and translocates into the nucleus to mediate 
transcriptional activation of genes involved with suppression of hunger and energy expenditure. 
Leptin also targets receptors found on peripheral (non-hypothalamic) tissues, and has been 
demonstrated to regulate bone mass and inflammation in mice (Iikuni et al., 2008). 
Mice expressing a nonsense mutation at the leptin gene (Lepob/ob) specifically on a 
C57BL/6J genetic background develop spontaneous obesity and insulin resistance with age, but 
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do not develop severe diabetes (Keller et al., 2008). In contrast, the same mutation on a BTBR 
genetic background results in severely hyperglycemic by week 10 (Hudkins et al., 2010). Strikingly, 
C57BL/6J Lepob/ob mice display enhanced β cell proliferation and increased β cell mass compared 
with control lean mice, an effect which is absent in diabetic BTBR Lepob/ob mice of the same age 
(Keller et al., 2008). Additional transgenic and conditional null mutant studies in obese diabetic 
mice expressing a nonsense mutation at the leptin receptor gene (Leprdb/db) demonstrate that 
overexpressing a constitutively active form of Cdk4 or deleting the cell cycle inhibitor p27 improves 
hyperglycemia through increased β cell replication (Miyawaki et al., 2008; Uchida et al., 2005). 
Furthermore, lineage tracing of β cell expansion in an additional mouse model of obesity (a 
tamoxifen-inducible whole-body knock-out of the leptin receptor using Ubc-CreERT2; LepRfl/fl) 
demonstrated that β cell expansion in response to acute leptin receptor deficiency is contributed 
by increased β cell proliferation and not neogenesis from precursor cells (Cox et al., 2016). 
Altogether, these data demonstrate that adaptive β cell proliferation is a necessary compensatory 
mechanism during obesity development in rodents.  
 Multiple extracellular and intracellular signaling pathways have been shown to stimulate 
compensatory β cell proliferation during obesity and prediabetes development. Glucose 
metabolism itself has a mitogenic effect on β cells. A recent study using in vivo genetic and 
pharmacological approaches determined that glycolytic flux is necessary for compensatory β cell 
replication (Porat et al., 2011). Ablation of glucokinase, the enzyme responsible for the very first 
and rate-limiting of step of glycolysis, specifically in the β cells (Insulin-CreERT2; Gckfl/fl mice) resulted 
in decreased proliferation despite the development of hyperglycemia. Activation of glucokinase in 
wild-type animals using the pharmacological compound Ro28-1675 led to an increased rate of 
glycolysis independent of circulating blood glucose levels. This treatment led to an increase in β 
cell proliferation that was strictly dependent on membrane depolarization and Ca2+ influx, 
suggesting that glucokinase activity promotes β cell replication through calcium signaling. The 
Ca2+-dependent calcineurin/NFAT signaling pathway has been extensively studied in the context 
of β cell proliferation during aging and diet-induced obesity (Heit et al., 2006; Wang et al., 2015a; 
Yang et al., 2006). Overexpression, conditional null mutation, and pharmacological intervention 
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models demonstrated that mitogenic genes important for β cell proliferation were regulated by 
calcineurin/NFAT signaling. Thus, glucokinase-mediated cell replication may be highly relevant in 
obesity due to persistent hyperglycemia and increased glucose flux, which would lead to increased 
calcineurin/NFAT signaling.  
 In addition to increased glycolytic flux, increases in circulating growth factors such as 
hepatocyte growth factor (HGF) may also stimulate β cell proliferation during obesity. HGF targets 
the c-Met tyrosine kinase receptor on the surface of β cells, and has been shown to activate pro-
proliferative transcriptional activators Stat5 and FoxM1 during states of metabolic demand such as 
pregnancy and streptozotocin-induced hyperglycemia (Demirci et al., 2012). Mice harboring a 
pancreatic deletion of the c-Met receptor (Pdx1-Cre;Metfl/fl) had impaired β cell proliferation and 
glucose tolerance compared to control mice during pregnancy. Transgenic mice overexpressing 
HGF under the rat insulin promoter (RIP-HGF) displayed an increased rate of β cell proliferation 
compared to control animals, and were protected from streptozotocin induced hyperglycemia 
(Garcia-Ocaña et al., 2000). During obesity, adipocyte secretion of HGF is elevated and positively 
correlated with both rodent and human BMI (Garcia-Ocaña et al., 2000; Rehman et al., 2003). 
Inhibiting HGF signaling via c-Met receptor inhibitor SU11274 resulted in suppression of high fat 
diet-induced β cell replication, thus demonstrating the importance of HGF for compensatory β cell 
proliferation (Araújo et al., 2012). 
 
Pathological β cell hyperplasia 
 
 Elucidating the mechanisms underlying adaptive β cell proliferation in metabolically 
challenged adult mice have revealed key signaling pathways that may provide a strategy for β cell 
expansion. Likewise, investigating the genetic, epigenetic, and molecular etiology of human 
pathologies characterized by β cell hyperplasia can also reveal interesting and exploitable pro-
proliferative pathways. The mechanisms underlying two disorders distinguished by β cell 
hyperproliferation, Beckwith-Wiedemann Syndrome and pancreatic neuroendocrine insulinoma, 
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are further explored below. Notably, both disorders are frequently caused by transcriptional 
dysregulation of CDKN1C, which encodes for the prominent β cell cycle inhibitor p57.  
 
Beckwith-Wiedemann Syndrome  
 Beckwith-Wiedemann Syndrome (BWS) is a congenital overgrowth syndrome that affects 
1 in 13,700 newborns worldwide (Weksberg et al., 2010). Newborns with BWS are born heavier 
than the average newborn and have abdominal wall defects at birth. As they develop, children with 
BWS display a wide spectrum of clinical features varying in size and severity, but are often 
characterized by abnormal (and sometimes asymmetrical) enlargement of the tongue, liver, 
pancreas, spleen and other internal organs. They are also at increased risk for developing rare 
cancers, such as hepatoblastoma and renal cancer. Approximately half of BWS patients are 
diagnosed with hyperinsulinism, resulting in hypoglycemia that usually resolves with age (Hussain 
et al., 2005). However, a small proportion of BWS patients require pancreatectomy to surgically 
remove large portions of the pancreas; these pancreata contain remarkable hyperplasia and 
hypertrophy of the β cells, explaining the presence of hyperinsulinemic hypoglycemia (Laje et al., 
2013; Munns, 2001).  
The wide variation in symptoms can be explained by the complex genetic background of 
BWS, which is frequently caused by abnormalities at chromosomal region 11p15.5 (Cooper et al., 
2005; Enklaar et al., 2006). Chromosomal region 11p15.5 (chr11p15.5) is extraordinary due to the 
presence of two separate genomically imprinted clusters that are controlled by the Imprinting 
Control Region 1 (ICR1) or Imprinting Control Region 2 (ICR2). Of the entire human genome 
containing approximately 20,000 genes, fewer than 100 have been identified to be regulated by 
genomic imprinting - an epigenetic mechanism that regulates mono-allelic expression of an allele 
inherited from a specific parent due to epigenetic silencing of the imprinted allele (Bartolomei and 
Ferguson-Smith, 2011). Paternally imprinted genes are epigenetically silenced on the paternally-
inherited allele and are thus expressed preferentially from the maternally-inherited allele; 
conversely, maternally imprinted genes are expressed preferentially from the paternally-inherited 
allele. Imprinted genes are often grouped in clusters that are regulated by a common imprinting 
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control region, which is a DNA methylation-sensitive regulatory element that is differentially 
methylated on the paternal and maternal allele. At least two imprinting mechanisms have been 
implicated in the BWS susceptibility locus at chr11p15.5: non long-coding RNA (lncRNA)-mediated 
transcriptional silencing in cis, and CTCF-mediated transcriptional regulation and insulator 
formation (Shmela and Gicquel, 2013). Abnormal methylation at the ICR1 or ICR2 on chr11p15.5 
results in disrupted genomic imprinting at the locus, leading to dysregulated bi-allelic expression of 
genes that are normally imprinted and silenced at one allele. Disrupted imprinting at the ICR1 and 
ICR2 is the most frequent genetic cause underlying β cell hyperplasia in the BWS patients (75% of 
cases), while deleterious mutations at the cell cycle inhibitor CDKN1C/p57 gene account for 5% of 
BWS cases (Weksberg et al., 2010).  
Hypermethylation of the ICR1 accounts for 5% of Beckwith-Wiedemann cases due to 
abnormal bi-allelic expression of insulin-like growth factor (IGF2), which is important for fetal 
development and growth (Figure 1.2). Normally, the ICR1 is unmethylated on the maternal allele 
and acts as a chromatin insulator, facilitated by maternal-specific binding CTCF (Bartolomei et al., 
1991; Kurukuti et al., 2006). Binding of CTCF at the ICR1 prohibits a downstream enhancer from 
looping to the IGF2 promoter, thus blocking transcription of IGF2, and instead allows that same 
enhancer to loop and promote expression of non-coding RNA H19. On the paternal allele, CTCF 
cannot bind to methylated ICR1, thus allowing IGF2 promoter-enhancer interaction to occur, driving 
preferential expression of IGF2 on the paternal allele. In BWS, hypermethylation of the ICR1 results 
in abnormal loss-of-imprinting of IGF2, contributing to the overgrowth of β cells and other organs. 
Hypomethylation of the ICR2 on the maternal allele is the leading cause of BWS, and is 
detected in approximately 50% of cases (Weksberg et al., 2010). The ICR2 is a CpG-dense 
regulatory element located at the promoter of long non-coding RNA KCNQ1OT1, and is 
hypomethylated on the paternal allele (Figure 1.2). The unmethylated status of the ICR2 correlates 
with preferential expression of KCNQ1OT1 on the paternal allele, and transcriptional silencing of 
CDKN1C/p57, PHLDA2, SLC22A18, and KCNQ1 (in certain tissues) on the same allele (Pandey 
et al., 2008). Conversely, methylation of the ICR2 on the maternal allele correlates with preferential 
maternal expression of CDKN1C/p57 and the other nearby genes, while KCNQ1OT1 remains 
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maternally imprinted and silenced. While ICR2 deletion studies in mice demonstrate clearly that 
the ICR2 itself is necessary for imprinting CDKN1C (Fitzpatrick et al., 2002), the molecular 
mechanisms governing ICR2-mediated imprinting are complex and poorly understood, especially 
in adult tissues. Conflicting studies in pre- and postnatal mice have suggested several regulatory 
mechanisms that facilitate paternal imprinting of CDKN1C.  
Early in vitro studies using luciferase and enhancer blocking assays demonstrated that the 
ICR2 (also inconsistently called the “KvDMR” and the “Kcnq1 ICR”) displayed methylation sensitive 
silencer function and Kcnq1ot1 promoter activity, although it was unclear at the time whether 
Kcnq1ot1 was necessary to drive transcript-dependent chromatin silencing in cis (Kanduri et al., 
2002; Mancini-DiNardo et al., 2003; Thakur et al., 2003). In a follow-up study, a mouse containing 
a deletion of the entire ICR2 (ICR2Δ) was generated on a C57BL/6 genetic background (Mancini-
Dinardo et al., 2006). By crossing C57BL/6 male ICR2Δ mice to female Mus spretus mice, F1 hybrid 
offspring inherit deletion of the ICR2 specifically on the paternal allele while simultaneously 
inheriting M. spretus associated polymorphisms on the maternal allele, allowing for allele-specific 
detection of gene expression. The opposite cross using C57BL/6 female ICR2Δ mice and male 
Mus spretus mice was also generated as a control since the ICR2 is normally methylated and its 
promoter activity deactivated on the maternal allele; maternal ICR2 deletion should not impact 
expression of the nearby coding genes. Paternal transmission of ICR2Δ resulted in ablated 
expression of Kcnq1ot1 and bi-allelic expression of Cdknc1c and other nearby coding genes. In 
contrast, maternal transmission of the DMRΔ allele did not affect maternal mono-allelic expression 
of Cdkn1c and other nearby genes, demonstrating that the paternal, unmethylated ICR2 is 
necessary for imprinting. To demonstrate that expression of Kcnq1ot1 is necessary for imprinting, 
the authors generated two additional mice: a mouse carrying a 244 bp deletion of the previously 
mapped Kcnq1ot1 promoter, leaving the remainder of the ICR2 intact (PromΔ), and a mouse that 
expresses a severely truncated form of Kcnq1ot1 - normally 60-70 kb long - via the insertion of a 
poly(A) transcriptional termination site 1.5 kb downstream of the transcription start site (Mancini-
Dinardo et al., 2006). Paternal transmission of either the PromΔ or the truncated Kcnq1ot1 alleles 
resulted in activation of the nearby genes on the paternally-inherited allele, demonstrating that 
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transcription of full length Kcnq1ot1 is necessary for imprinting. A few years later, a mechanism for 
Kcnq1ot1-mediated transcriptional silencing in cis was identified: Kcnq1ot1 transcripts recruit 
histone methyltransferases PRC2 and G9a, as well as DNMT1, to facilitate chromatin silencing via 
CpG methylation, H3K27me3, and H3K9me3 repressive histone methylation (Mohammad et al., 
2010; Pandey et al., 2008).  
However, other studies suggest that paternal imprinting of Cdkn1c is mediated by a 
mechanism independent of Kcnq1ot1. In a study independent of the one described above, another 
mouse expressing a truncated form of Kcnq1ot1 was generated with a poly(A) termination site 
inserted 2.6 kb downstream of the Kcnq1ot1 transcription start site (Shin et al., 2008). Several 
embryonic tissues including the heart, brain, and gut had disrupted imprinting of Cdkn1c following 
paternal transmission of the truncated Kcnq1ot1 allele. Strikingly, imprinting of Cdkn1c on the 
paternal allele was maintained in other embryonic tissues such as the liver, kidney, and fibroblasts 
in the same animals. Imprinting of Slc22a18 and Kcnq1 was disrupted in all embryonic tissues, 
suggesting that Cdkn1c specifically is silenced on the paternal allele through a mechanism 
independent of Kcnq1ot1 in a tissue-specific manner.  
An additional study conducted by the same group as above validated that the ICR2 
contains two CTCF binding sites, and that there was preferential binding of CTCF on the 
hypomethylated maternal allele (Fitzpatrick et al., 2007). This suggests that the ICR2 may function 
as a chromatin insulator similar to the ICR1. Interestingly, publicly available genome-wide 
chromosome capture Hi-C data point to an interaction between the ICR2 and the CDKN1C locus 
(Wang et al., 2017b), and the interaction sites correspond to known CTCF binding sites identified 
through chromatin immunoprecipitation (Figure 1.3). However, additional studies are necessary to 
demonstrate maternal-specific looping between the ICR2 and CDKN1C promoter, and what 
regulatory elements within the loop promote CDKN1C expression. Perhaps the evolution of a 
second, lncRNA-independent mechanism regulating the imprinting of CDKN1C/p57 is necessary 
due to the importance of precise p57 levels during embryonic development; too much p57 leads to 
growth retardation as seen in Silver-Russell Syndrome, whereas too little p57 results in overgrowth 
disorders such as BWS (Õunap, 2016).  
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While the imprinting mechanism regulating the mono-allelic expression of CDKN1C is a 
controversial topic, it is clear that loss of CDKN1C expression results in abnormal proliferation of 
different cell types and tissues, including the β cells.  
  
Insulinoma  
 While classified as the most common pancreatic endocrine tumor, insulinomas are still very 
rare. Four new cases of insulinomas are identified each year per million of patients. They are 
characterized by β cell hyperplasia leading to the development of small tumors (< 2 cm in size) that 
are 90% benign (Okabayashi, 2013). Immunocytochemistry staining for Ki-67 in pancreatic tissue 
sections revealed a 34-fold increase in β cell replication rate in insulinoma β cells (3.71%) 
compared with normal β cells (0.11%) (Ueberberg et al., 2016). Insulinoma is the most common 
cause of hypoglycemia in adults that do not take anti-diabetic drugs due to the excessive production 
and dysregulated secretion of insulin, even during a fasted state (Okabayashi, 2013). In fact, in 
1979 Dr. Axel Ullrich, a German cancer biologist recognized as the first person to ever clone a 
human gene (insulin) into E. Coli, had purified insulin mRNA from a surgically extracted insulinoma 
sample (Cheng, 2009). After transforming E. coli bacteria with a vector containing the cloned cDNA 
of insulin, Dr. Ullrich had synthesized and produced the world’s first recombinant insulin for diabetic 
patients.  
Approximately 5% of insulinoma cases are associated with multiple endocrine neoplasia 
type 1 syndrome (MEN1), a hereditary cancer of different endocrine organs including the pancreatic 
islets (Demeure et al., 1991). MEN1 is caused by loss-of-function missense mutations or deletions 
in the Menin tumor suppressor gene, which was previously mentioned to regulate expression of 
cell cycle inhibitors p18 and p27 through H3K4 promoter methylation (Karnik et al., 2007). Menin 
also binds to and blocks activity of JunD (Agarwal et al., 1999; Huang et al., 2012), a member of 
the Jun family of transcriptional activators that form homodimers or heterodimers with the Fos or 
ATF protein families. Different assemblies of Jun, Fos, and ATF dimers form the AP-1 transcription 
factor, which plays an instrumental role in the transcriptional activation of genes involved with 
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proliferation, apoptosis, and differentiation. Several missense mutations in Menin disrupts JunD 
binding (Huang et al., 2012), permitting dimerization with other components of pro-proliferative AP-
1. Absence of Menin due to genetic mutations results in uncontrolled cell cycle in endocrine cells 
due to abnormal regulation of cell cycle genes. Because of its important role in regulating β cell 
cycle, pharmacological inhibition of Menin has been proposed as a therapeutic strategy for β cell 
expansion. 
Additional studies have identified other dysregulated cell cycle genes found in non-MEN1 
insulinomas. One such study used a parallel approach of gene expression analysis via real time 
quantitative polymerase chain reaction (RT-qPCR) and immunocytochemistry validation to identify 
differences in levels of cell cycle regulators between the insulinoma and healthy β cells (Ueberberg 
et al., 2016).  There was a striking decrease in both expression and protein levels of p16 in the 
insulinoma samples, an interesting but not too surprising discovery due to p16’s role in age-
associated decline in β cell proliferation. The decrease in p16 expression correlates with aberrant 
DNA hypermethylation at the p16 promoter. Strikingly, promoter hypermethylation at the p16 locus 
has also been identified in several other cancers (Shao et al., 2014; Wang et al., 2012). The 
increase in p16 promoter methylation may be related to the increase in the copy number of EZH2, 
a component of the Polycomb Repressive Complex 2 which trimethylates H3K27, a common 
mutation in insulinomas detected by whole exome sequencing of 38 insulinoma samples (Wang et 
al., 2017a). While there is limited knowledge on the biochemical readers that co-regulate 
H3K27me3 and DNA methylation, there is emerging evidence that the two epigenetic marks are 
interrelated and function together to silence chromatin (Rose and Klose, 2014).  
 β cells from insulinomas also had significantly decreased levels of p57, a cell cycle inhibitor 
implicated in other β cell hyperplasia disorders (explained in more detail below). The loss of p57 
expression was also observed in the majority of pediatric MEN1-associated and non-MEN1 
insulinomas (Bhatti et al., 2016). Whole exome sequencing identified frequent loss-of-copy 
(through deletion) and copy-neutral loss-of-heterozygosity (copy-neutral LOH) somatic mutations, 
which is consistent with what has been reported in the pediatric insulinomas (Wang et al., 2017a). 
Copy-neutral (defined as no change in allele copy number, remaining as two copies) LOH is the 
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loss of the wild-type allele in a heterozygous individual that already carries a non-functioning allele 
at the same locus. The loss of the wild-type allele arises from two common mechanisms: a 
spontaneous deleterious mutation at the wild-type allele, or an error during genetic recombination 
that results in acquired homozygosity of the non-functioning allele due to incorrect duplication of 
that chromosomal segment. The latter mechanism is termed “uniparental isodisomy” (UPD), and 
can be further characterized by paternal or maternal UPD depending on the parental origin of the 
duplicated chromosome. Insulinomas with aberrations in p57 expression are often caused by 
paternal UPD of chromosome 11p15.5 (Wang et al., 2017a). The unique, genomically-imprinted 
status of p57 expression contributes to the locus’ vulnerability for copy neutral LOH and insulinoma 
risk. Additionally, methylation analysis of ten insulinoma samples detected global hypomethylation 
at the imprinted chromosome 11p15 locus, which is consistent with the methylation abnormalities 
seen in Beckwith-Wiedemann Syndrome (Wang et al., 2017a). Altogether, these findings suggest 
that p57 is a critical cell cycle regulator in β cells, and perhaps targeted modulation of p57 activity 
can induce β cell proliferation.  
Overall, identifying pathways that can be manipulated to induce adult β cell proliferation 
can potentially lead to successful production of transplantable β cells for the treatment of diabetes. 
In the first part of my thesis, I describe how overexpression of ST5, an activator of the mitogenic 
MAPK/ERK signaling, did not result in increased mouse β cell proliferation under basal and 
metabolically challenged conditions. However, in the second part of my thesis, I describe how 
deactivation of CDKN1C/p57 through targeted demethylation of the ICR2, an epimutation 
commonly found in BWS patients, successfully induced human β cell replication. Altogether, these 
results suggest that targets identified from naturally occurring human disease characterized by β 
cell hyperplasia hold more therapeutic potential for the treatment of diabetes. 
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Table 1.1 Pancreatic endocrine cell types.  
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Table 1.2 Mutations in MODY.  
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Figure 1.1 Human β cell proliferation with age.  
 
 
  
From Saunders D, Powers AC. Replicative capacity of β cells and type 1 diabetes. J Autoimmun. 2016  
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Figure 1.2 Schematic of imprinted domains in chromosomal region 11p15.5.  
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ICR2 
Figure 1.3 Hi-C data of chromosomal region 11p15.5 in human fibroblasts.  
 
 
 
 
 
 
  
CDKN1C 
Hi-C data from the 3D Genome Browser (Wang et al., 2017b) suggest an interaction between the 
ICR2 and CDKN1C promoter. This may support evidence for differential CTCF binding at the 
Imprinting Control Region 2.  
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CHAPTER TWO 
 
Materials and methods 
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MATERIALS AND METHODS FOR ST5 OVEREXPRESSION STUDIES (CHAPTER 3) 
 
Animals 
Tre-ST5 transgenic mice were derived by engineering a TRE (Tetracycline Response Element) 
cassette upstream of the cDNA encoding the longest isoform of human ST5, p126. RIP (Rat Insulin 
Promoter)-rtTA mice were purchased from the Jackson laboratory. All mice were maintained on a 
mixed 129SvEv/C57BL/6 background. Genotyping was performed by PCR analysis using genomic 
DNA isolated from the tail tips of newborn mice using the primers in Table 2.1.  
 
Adult mice (12-16 wk of age) were used in all experiments unless otherwise noted. To induce ST5 
expression, doxycycline (Dox, Sigma #D9891) was administered via the drinking water at 1 g/L and 
replenished twice a week. For both pregnancy and streptozotocin (STZ) studies, mice were kept 
on Dox+ water for two weeks, starting from gestational day 0.5 in females and the first injection day 
of STZ in males, respectively. For the STZ study, both ST5 OE and control mice were 
intraperitoneally injected daily for four consecutive days with 85 μg/gram body weight of freshly 
dissolved STZ (Sigma # S0130) in 0.1 M sodium citrate (pH 4.5).  
 
To label proliferating β cells in STZ-treated animals, 1 g/L of BrdU (Sigma #B5002) was 
administered via the drinking water for one week prior to sacrifice of the mice. For studies on basal 
metabolic state and during pregnancy, a shorter BrdU labeling was performed as the follows: 
animals were treated by intraperitoneal injection of BrdU (30 μg per gram body weight) 16 hours 
prior to sacrifice. All procedures involving mice were conducted in accordance with approved 
Institutional Animal Care and Use Committee protocols.  
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Physiological Studies 
 
Blood glucose levels during ad libitum feeding and glucose tolerance tests were measured as 
previously described (Gao et al., 2010; Le Lay et al., 2009) 
 
Histological Analysis 
For all histological studies, pancreata were dissected and fixed in 4% paraformaldehyde overnight 
at 4°C before paraffin embedding and sectioning with the maximum pancreatic footprint. Tissues 
were sectioned to 5 μm thickness. Antigen retrieval was performed in citric acid buffer pH 6.0 in the 
2100 Classic Clinical Autoclave (Prestige Medical) for one hour, followed by 15 min cooling in 
running water. All slides were blocked with Casblock (Thermo Fisher Scientific #00-8120) for 10 
min at room temperature. To quantify β-cell proliferation, dual immunofluorescent staining was 
performed for insulin and BrdU or Ki67. The primary antibodies [guinea pig anti-insulin (1:1,300, 
Invitrogen #180067) and rat anti-BrdU (1:500, AbD Serotec #OBT0030G)] or mouse anti-Ki67 
(1:500, BD pharmacology #550609) were diluted in Casblock and incubated with the tissue sections 
overnight at 4°C. Secondary antibody incubation was performed with species-specific fluorophore-
labeled secondary antibodies (1:500, Jackson ImmunoResearch Laboratories) for two hours at 
room temperature.  Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole) (Thermo Fisher 
Scientific #D1306). β-cell proliferation was calculated by dividing BrdU/insulin or Ki67/insulin 
double-positive cell number by insulin-positive cell number within islets. At least two sections from 
each animal were manually counted, and 3-4 animals from each genotype were analyzed. Pdx1 
and ST5 antibody staining was performed as described above using the following primary 
antibodies: goat anti-Pdx1 (1:1,000, Santa Cruz #sc-14664) and rabbit anti-ST5 (1:200, Abcam # 
ab111556). 
 
To quantify the ratio of insulin+ area to islet area, whole pancreata were removed, laid out flat and 
fixed as above. Five-micron longitudinal sections were prepared, with 50-micron intervals between 
sections. Every sixth section (a total of 3-4 sections per pancreas) was used for hormone 
immunofluorescent labeling. This sampling method spans over 50% of the pancreatic volume. In 
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addition, care was taken to score equivalent regions of control and mutant specimens. After 
immunofluorescent staining, 100% of each hormone-labeled section was scanned at 4X 
magnification. The areas of positive signal and the total pancreatic areas were measured by Image 
J (Schneider et al., 2012). β-cell mass was derived from the total pancreas weight multiplied by the 
percentage of β-cell area relative to the whole pancreatic area.  
 
RNA Extraction and RT-qPCR    
We isolated mouse pancreatic islets by intra-ductal collagenase perfusion using standard methods 
(Gao et al., 2010). Total RNA from mouse islets was extracted using RNeasy Mini Kit (Qiagen 
#74104) and analyzed by qRT-PCR as described previously (Gao et al., 2010; Le Lay et al., 2009). 
qRT-PCR primer sequences are listed in Table 2.1. 
 
Statistical Methods 
Statistical analysis between two groups was performed using a two-tailed Student’s t-test unless 
noted otherwise. Values were considered significant when P< 0.05. Data are shown as mean 
plus standard error of the mean.  
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Table 2.1 Primers for ST5 study  
Gene Forward Primer (5’ - 3’) Reverse Primer (5’ - 3’) 
Genotyping 
RIP-rtTA 
GTGAAGTGGGTCCGCGTACAG GTACTCGTCAATTCCAAGGGCATC
G  
Genotyping 
TRE-hST5 
CATCCACGCTGTTTTGACCTC CTCCAAAGGGTGTGAAATCCA 
RT-qPCR 
human ST5 
TTAAAGCCATCGCCACAAC CATGGTCATTTCGGCTCTCT 
RT-qPCR 
mouse ST5 
CCCAGACTCCGTCAGTTTCT GGGCATCATTCTCTGTCTGG 
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MATERIALS AND METHODS FOR TARGETED EPIGENETIC EDITING STUDY (CHAPTER 4) 
 
TALE-TET1 construction  
The TALE target sequence was selected by inserting the genomic sequence of the ICR2 (hg19 
chr11:2720411-2722087) into the TAL Effector-Nucleotide Targeter 2.0 online tool (Doyle et al., 
2012). The binding site sequence 5’-TGCTGACCGTGTTCAAACCC-3’ was selected due to 
predicted minimal off-target binding elsewhere in the genome. The coding sequence of the TALE 
repeat domain was jumbled as previously published (Bernstein et al., 2015) to minimize 
recombination events during lentivirus transfer plasmid propagation. The final sequence of the 
TALE repeat domain was synthesized by Eurofins Genomics and cloned into pTALE-TFv2 
(Addgene #32188). The SV40-NLS-VP64 element was replaced by the SV40-NLS-TET1 active 
and inactive (TET1dead) catalytic domain (amplified from Addgene plasmids 49239 and 49965) using 
restriction enzyme digest and ligation.  
 
Lentivirus production 
The complete ICR2 TALE-TET1 or TALE-TET1dead sequence was inserted into the pLU-EF1α-eGFP 
lentivirus transfer plasmid (Wistar Expression Core) by restriction enzyme digest and ligation. The 
transfer plasmid was then modified by removing the IRES-eGFP element to accommodate the 
limited packaging size. Lentiviral particles were generated by co-transfecting HEK293T cells with 
pLU-ICR2-TALE-TET1 or pLU-ICR2-TALE-TET1dead, psPAX2, and pMD2.G (Addgene). Lentiviral 
particles were harvested 24 and 48 hours after transfection, and concentrated by 
ultracentrifugation. Viral titers were estimated by ELISA using the LentiX p24 Rapid Titer Kit 
(Clonetech).  
 
Adenovirus production 
Adenovirus was generated using the AdEasy system (Agilent). Briefly, the ICR2 TALE-TET1 or 
TALE-TET1dead sequences were sub-cloned into the pAdTrack-CMV shuttle vector (Addgene 
#16405). Due to the packaging constraints of adenoviral genome, the CMV GFP elements were 
replaced by IRES-GFP (amplified from pLU-EF1α-eGFP), which was cloned directly downstream 
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of the stop codon of the TET1 catalytic domain. The purified pAdTrack-ICR2-TALE-TET1-IRES-
GFP plasmid was linearized by PmeI digestion and electroporated into BJ5183-AD-1 cells (Agilent) 
containing the AdEasy1 destination adenoviral packaging plasmid. Recombinant plasmids were 
screened by restriction digest and Sanger sequencing. ElectroMAX DH10B cells (Thermo Fisher 
Scientific) were electroporated with the recombinant AdEasy1 plasmid for large scale production. 
Adenoviral particles were generated by transfecting HEK293T cells with linearized recombinant 
plasmid as previously described (Luo et al., 2007). After two rounds of amplification, adenoviral 
particles were isolated and concentrated using Fast-Trap Virus Purification and Concentration Kit 
(Millipore). Viral titers were determined by flow cytometry.    
 
HEK293T transfection  
HEK293T cells were seeded in 60mm dishes at 2.8x106 cells the evening prior to transfection. Cells 
were transfected with 10 ug of pAdTrack.ICR2-TET1, pAdTrack.ICR2-TET1dead, or pAdTrack.TET1-
cd plasmids using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. GFP+ cells were collected by fluorescence-activated cell sorting 72 hours after 
transfection. RNA was isolated using the RNeasy Mini Kit (Qiagen), and cDNA generated using the 
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Changes in gene 
expression were assessed by real time quantitative PCR using Brilliant III Ultra Fast QPCR Master 
Mix (Agilent).  
 
Human fibroblast transduction  
Human foreskin fibroblasts were purchased from ATCC (CRL-2522) and cultured in 10% FBS in 
IMDM (Thermo Fisher Scientific). Fibroblasts were seeded at 1.5x105 cells/well in a 6-well plate the 
evening before lentivirus or adenoviral transduction. Cells were infected at an MOI of 50 with 
Polybrene reagent (Sigma Aldrich). RNA and genomic DNA were harvested 72 hrs later using the 
AllPrep DNA/RNA Mini Kit (Qiagen). cDNA synthesis and RT-qPCR were performed as described 
above.  
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Targeted bisulfite sequencing 
Targeted bisulfite sequencing primers were designed manually using MethPrimer (Li and Dahiya, 
2002) with partial adapter overhangs as described in Bernstein, DL et al (Bernstein et al., 2015). 
100 ng of genomic DNA isolated from sorted cells were bisulfite converted using EZ DNA 
Methylation-Gold Kit (Zymo Research). Targeted ICR2 regions were amplified using the PyroMark 
PCR Kit (Qiagen), and gel purified using QIAquick Gel Extraction Kit (Qiagen). Libraries were 
barcoded using the Indexing Primer Set HT for Illumina (Takara), and library concentrations and 
fragment lengths were verified by Qubit (Thermo Fisher Scientific) and High Sensitivity DNA 
BioAnalyzer (Agilent), respectively.  Next-generation sequencing and analysis was carried out as 
previously described (Bernstein et al., 2015). Primers are listed on Table 2.2.  
 
Western blot  
Fibroblasts were seeded and transduced as described above. After 72 hours, cells were lysed with 
RIPA buffer (Cell Signaling Technology) supplemented with PMSF (Roche). Western blot was 
performed using the NuPAGE electrophoresis system (Invitrogen) with a 4-12% Bis-Tris acrylamide 
gel. After electrophoresis, proteins were transferred onto a nitrocellulose membrane using the iBlot 
Dry Blotting System (Invitrogen) for 7 minutes. The membrane was blocked with 5% milk in tris-
buffered saline with 0.1% Tween 20 (TBST) and incubated with an anti-p57 primary antibody 
(Abcam ab75974, 1:100) overnight at 4 degrees. After washing with TBST, the membrane was 
incubated with Peroxidase AffiniPure Goat Anti-Rabbit IgG (Jackson ImmunoResearch, 1:5,000) 
secondary antibody at room temperature for 1 hour. The membrane was washed and imaged with 
Luminata Crescendo Western HRP Substrate (Millipore). The membrane was then stripped and 
re-blotted for Vinculin (Cell Signaling Technology #4650, 1:1,000).  
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EdU incorporation assay 
For proliferation studies, fibroblasts were seeded at 50% confluency on 13mm sterilized Nunc 
Thermanox Coverslips (Thermo Fisher Scientific) placed in a 24-well plate. Fibroblasts were 
transduced with lentivirus for 24 hrs. After transduction, fibroblasts were serum starved with 1% 
FBS in IMDM for 48 hours to arrest and sync the cell cycle. After replacing the serum-depleted 
media with regular growth media, fibroblasts were allowed to grow for an additional 48 hrs. During 
the last hour of growth, fibroblasts were pulsed with EdU to label proliferation. Cells were fixed with 
4% paraformaldehyde and EdU incorporation was visualized using the Click-iT Plus EdU Alexa 
Fluor kit according to the manufacturer’s protocol (Thermo Fisher Scientific). Cells were imaged on 
the Keyence All-in-One Fluorescence microscope using a 0.2 NA 4X objective (Nikon).  
  
RNA fluorescent in situ hybridization  
Human KCNQ1OT1 Stellaris FISH probes with Quasar 670 Dye were purchased from LGC 
Biosearch Technologies. Fibroblasts were seeded and transduced with Ad.ICR2-TET1 or Ad.ICR2-
TET1dead for 72 hours in a 6 cm dish before fluorescence-activated cell sorting using the BD 
FACSAriaII. GFP+ cells are seeded onto Poly-L-Lysine treated glass slides for 24 hours before 
fixing in 4% paraformaldehyde. Hybridization steps were carried out as previously described (Raj 
et al., 2008). Images of cells were acquired using a 1.4 NA 63X oil-immersion objective (Leica) on 
a Leica wide-field fluorescence microscope. Coordinates of all captured images were saved and 
used for imaging DNA FISH.  
 
Oligopaint DNA fluorescent in situ hybridization 
Probe libraries were designed using the Oligopaint pipeline with the default parameters of 
OligoMiner (Beliveau et al., 2012, 2018). Specifically, 42 nucleotide sequences with homology to 
the region of interest were mined from the hg38 genome build.  The probe library targeted a 100 
kb region of sequence. Oligopaints were synthesized as previously described (Rosin et al., 2018). 
Slides that had already been imaged for KCNQ1OT1 RNA FISH were pre-denatured in 
2×SSCT/50% formamide at 92° for 2.5 minutes, then in 2×SSCT/50% formamide at 60° for 20 
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minutes. Oligopaint hybridization and visualization steps were carried out as previously described 
(Rosin et al., 2018).  
 
 
Human islet transduction  
Human islets from non-obese, non-diabetic organ donors were obtained from the Integrated Islet 
Distribution Program. Islets were cultured in suspension using Prodo Standard Islet Media (Prodo 
Laboratories Inc). For whole islet gene expression and methylation analysis, 100 islets were picked 
for each group and transduced with Ad.ICR2-TET1 or Ad.ICR2-TET1dead adenovirus at an MOI of 
300. RNA and gDNA were isolated after 72 hours using the Qiagen Allprep DNA/RNA Mini Kit. 
Transduced GFP+ β cells were sorted by FACS as previously described (Bramswig et al., 2013).  
 
Immunofluorescent staining of dispersed islets 
Human islets were enzymatically digested with 0.05% trypsin and seeded on Poly-D-lysine treated 
glass coverslips placed in a 24-well plate. Dispersed cells were transduced with adenovirus (MOI 
= 300) for 72 hours after attachment to the coverslips. Cells were fixed with 4% paraformaldehyde, 
washed 3 times with cold PBS, permeabilized with PBST, and blocked with CAS-Block 
Histochemical Reagent (Thermo Fisher Scientific). Cells were stained for p57 (Abcam ab75974, 
1:150), GFP (Aves Labs GFP-1020, 1:300), C-peptide (Millipore 05-1109, 1:300), and Ki-67 
(Thermo Fisher SP6, 1:150) overnight at 4 degrees. After washing 3 times in PBST, cells were 
labeled with cyanine-conjugated secondary antibodies (Jackson ImmunoResearch, 1:600) and 
DAPI. After mounting onto microscope slides, cells were imaged with the Keyence All-in-One 
Fluorescence Microscope using a 1.4 NA 60X oil-immersion objective (Nikon).  
 
Whole islet insulin secretion 
Human islets were transduced with adenovirus for 72 hours prior to the perifusion procedure. 100 
islets were picked and perifused as previously described (Doliba et al., 2017) using Krebs-Ringer 
bicarbonate buffer (KRBB) media containing 3 mM glucose, 16.7 mM glucose, or 30 mM KCL in 
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addition to 0.25% BSA. Fractions were collected at 1 minute intervals for 120 minutes, and insulin 
content was determined using a radioimmunoassay. 
 
 
Single-cell glucose-stimulated calcium imaging  
Human islets were enzymatically dispersed and seeded onto glass bottom wells. After recovering 
for 48 hours, dispersed cells were transduced with adenovirus for 72 hours. Cells were loaded with 
fura-2AM during a 40 min pretreatment at 37 °C in 2 ml KRBB supplemented with 5 mM fura-2 
acetoxymethylester (Molecular Probes). Before perifusion with amino acid-supplemented media 
containing 3mM glucose, 16.7 mM glucose, or 30 mM glucose, an image was captured with the 
bright field and GFP channels to identify which single cells were successfully transduced with the 
virus. [Ca2+]i levels were measured by dual wavelength fluorescence microscopy in response to 
different perifusion conditions as previously described (Li et al., 2017).  
  
Xenotransplantation experiments 
Briefly, NSG mice (JAX) were fasted for 16 hours. The following morning, mice were 
intraperitoneally injected with pharmaceutical grade streptozotocin (Teva Pharmaceuticals) 
dissolved in 0.9% normal saline at a dose of 200 mg/kg of body weight. Three days after injection, 
hyperglycemic mice (blood glucose levels greater than 300 mg/dL) were shaved and anesthetized 
prior to making 2 small subcutaneous incisions at either side of the abdominal midline. For each 
group, 100 transduced islets were inserted subcutaneously in either incision, which were sealed by 
suturing. 
 
To label all proliferation events, mice were given BrdU (Sigma) through their drinking water at a 
concentration of 0.8 g/L, which was replaced twice a week. Abdominal skin sections containing 
human islets were harvested 21 days after transplantation, fixed overnight with 4% 
paraformaldehyde, and processed by paraffin sectioning. Histological analysis of slides was 
performed as previously described (Ou et al., 2018) using BrdU (Abcam ab6326, 1:300), C-peptide 
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(Millipore 05-1109, 1:300), and glucagon (Santa Cruz sc7779, 1:300). Images were captured on 
the Keyence All-in-One Fluorescence Microscope using the 0.95 NA 40X objective (Nikon).  
 
Statistics 
Student’s t-test using a two-tailed distribution, unless otherwise stated in the text or figure legends, 
was used to determine statistical significance. For all tests, a p-value < 0.05 was considered 
statistically significant. Data represent mean ± SEM. All analyses were conducted on GraphPad 
Prism 6. 
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Table 2.2. Primer sequences 
Primer Name Primer Sequence (5’-3’) Application 
CDKN1C_F GCGGCGATCAAGAAGCTGT  RT-qPCR 
CDKN1C_R GCTTGGCGAAGAAATCGGAGA  RT-qPCR 
KCNQ1OT1_F TGGCAATAGGGATGGAGGGA  RT-qPCR 
KCNQ1OT1_R ACCTCAAGCCCATCACCAAG  RT-qPCR 
MKI67_F TGGGGCAGGTTCTTAGTTTG  RT-qPCR 
MKI67_R AGGGGAGCCAGAAACTCAAT  RT-qPCR 
HPRT_F GCAGACTTTGCTTTCCTTGG  RT-qPCR 
HPRT_R AACACTTCGTGGGGTCCTTT  RT-qPCR 
ICR2_F1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTTTAGG
TTAGGTTGTATTGTTG 
Targeted 
bisulfite seq 
ICR2_R1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCAAC
ATAATTCTCCTC 
Targeted 
bisulfite seq 
ICR2_F2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTTTTTGGTA
GGATTTTGTTGA 
Targeted 
bisulfite seq 
ICR2_R2 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCACCCA
ACCAATACCTCATA 
Targeted 
bisulfite seq 
ICR2_F3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGTTATTT
ATTTGGTAAAGGG 
Targeted 
bisulfite seq 
ICR2_R3 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCAACACT
ATTTTTACAATCCAC 
Targeted 
bisulfite seq 
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CHAPTER THREE 
 
Overexpression of ST5, an activator of Ras, has no effect 
on β cell proliferation in adult mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from Ou K, Zhang J, Jiao Y, Wang ZV, Scherer P, and Kaestner KH. Overexpression of ST5, 
an activator of Ras, has no effect on β-cell proliferation in adult mice. Mol Metab. 2018. 
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Abstract 
Both Type I and Type II diabetes mellitus result from insufficient functional β cell mass. 
Effort to increase β cell proliferation as a means to restore β cell mass has so far met with limited 
success. Suppression of Tumorigenicity 5 (ST5), a Guanine Nucleotide Exchange Factor (GEF) 
protein, activates Ras/Erk signaling in the presence of Epidermal Growth Factor (EGF). In the 
pancreatic islet, Ras/Erk signaling is required for augmented β cell proliferation during pregnancy, 
suggesting that ST5 is an appealing candidate to enhance adult β cell proliferation. 
  We hypothesized that overexpression of ST5 drives adult β cell proliferation. To test this 
hypothesis, we utilized a doxycycline-inducible bi-transgenic mouse model to activate β-cell-
specific expression of human ST5 in adult mice at will. Islet morphology, β cell proliferation and 
mass in control and ST5-overexpressing (ST5 OE) animals were analyzed by immunofluorescent 
staining, under basal and two stimulated metabolic states, i.e. pregnancy and streptozotocin (STZ)-
induced β cell loss. 
Doxycycline treatment resulted in robust ST5 overexpression in islets from 12-16 week-old 
ST5 OE animals compared to controls, without affecting the islet morphology and identity of the β 
cell. Under basal state and during pregnancy, β cell proliferation and mass were comparable in 
ST5 OE and control animals. Furthermore, there was no detectable difference in β cell proliferation 
between ST5 OE and control animals in response to STZ-induced β cell loss. These findings 
demonstrate that ST5 overexpression by itself has no mitogenic effect on the adult β cell. 
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Introduction 
 
Two main forms of diabetes, Type I and Type II Diabetes can both be attributed to 
insufficient functional β cell mass. Identifying methods to promote β cell proliferation, especially in 
adults, have been an attractive therapeutic strategy for the treatment of diabetes. β cells, 
notoriously reluctant to proliferate in adulthood, are able to re-enter the cell cycle in response to 
metabolic challenges such as pregnancy (Parsons et al., 1992; Sorenson and Brelje, 1997), β cell 
damage (Tschen et al., 2009; Yin et al., 2006), and obesity (Golson et al., 2010; Linnemann et al., 
2014), at least in rodent models. Numerous elegant studies have detailed complex pathways 
governing adaptive β cell expansion (Bernal-Mizrachi et al., 2014; Kulkarni et al., 2012; Stewart et 
al., 2015), providing a basis for further investigations for candidate accelerators of adult β cell cell 
cycle. 
 HNF4α, a gene linked to Maturity Onset Diabetes of the Young (MODY), is one the 
transcription factors required for adaptive β cell proliferation during pregnancy in mice (Gupta et 
al., 2007). Suppression of Tumorigenicity 5 (ST5), a direct transcriptional target of Hnf4α, plays a 
role in one of the pathways thought to promote cell proliferation in response to the presence of 
mitogenic stimuli by mediating the activation of the Ras/ERK signaling cascade (Gupta et al., 2007). 
In humans, ST5 encodes three protein isoforms: p70, p82, and p126 (Lichy et al., 1992; Modi et 
al., 1991; Richard et al., 1993). While the short form of human ST5, p70, is associated with reduced 
tumorigenic phenotype in mammalian cell lines and was the reason for the naming of the gene 
(Lichy et al., 1992); the longest form, p126, activates MAPK/ERK in response to Epidermal Growth 
Factor (EGF) in COS-7 cells (Majidi et al., 1998). Mechanistically, the C-terminal GEF homology 
domain of p126 catalyzes the exchange of GDP to GTP in Ras, a small GTPase molecular switch, 
ultimately triggering the activation of the MAPK/ERK signaling cascade and thus inducing cell cycle 
entry (Majidi et al., 1998). Additionally, we have previously demonstrated that attenuated ST5 
expression in islets devoid of Hnf4α decreases Ras-GTP and phosphorylated ERK (pERK) levels 
(Gupta et al., 2007). 
 The EGF/Ras/ERK axis has long been proposed as a mitogenic pathway in the β cell. 
However, transgenic overexpression of EGF or its close family member HB-EGF induces drastic 
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transformation and disorganization of islets rather than substantial β cell proliferation (Gupta et al., 
2007; Krakowski et al., 1999; Means et al., 2003). It remains unclear how increased Ras/ERK 
activity in vivo affects β-cell proliferation in adulthood, in response to normal or high metabolic 
demand.  
In this study, we aimed to test the hypothesis that overexpression of the long isoform of 
ST5, an activator of the Ras/ERK pathway, is able to promote adult β cell proliferation.  We 
employed a doxycycline-inducible system to overexpress ST5 in β cells of adult mice and 
challenged the animals using two experimental paradigms of high metabolic demand. Our results 
demonstrate that overexpressing ST5 under both basal metabolic or challenged states is not 
sufficient to enhance β cell proliferation. 
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Results 
 
Inducible overexpression of ST5 in the adult β cell is not sufficient to enhance cell proliferation 
under basal condition. 
Because ST5 is a direct transcriptional target of Hnf4α during pregnancy-induced β cell 
replication and because ST5 deficiency leads to decreased ERK phosphorylation (Gupta et al., 
2007), we hypothesized that overexpression of ST5 could induce cell cycle entry in adult β cells. 
To test this notion, we developed a doxycycline-inducible mouse model to overexpress the longest 
isoform of human ST5, which is known to activate Ras/ERK signaling in the presence of EGF 
(Majidi et al., 1998), in β cells. This model is comprised of two transgenic lines: TRE-ST5 and RIP-
rtTA. Doxycycline induces ST5 expression in double transgenic animals specifically in the β cells. 
We kept 12-16 week-old double (ST5 OE) and single transgenic animals (control) on doxycycline 
(1 g/L) in drinking water for two weeks. The majority of  cells in islets from ST5 OE mice displayed 
robust ST5 expression, whereas β cells from control animals had non-detectable ST5 
immunoreactivity, as revealed by dual immuno-labeling of insulin and ST5 (Figure 3.1 A-F). In ST5+ 
β cells, we observed strong membrane and cytoplasmic signals for ST5, consistent with its 
previously reported role in Ras activation (Majidi et al., 1998) and the notion that activated Ras is 
anchored to the cytoplasmic face of the plasma membrane (Matallanas and Crespo, 2010). Gene 
expression analysis of RNA from isolated mouse islets further confirmed the induction of human 
version of ST5, without affecting the endogenous murine ST5 levels (Figure 3.1 J).  
Upon successful induction of ST5 expression, we sought to determine whether the β cell 
is able to tolerate high levels of ectopic protein expression. Immunocytochemistry staining showed 
strong insulin (Figure 3.1 D-F insets) and Pdx1 protein expression in both ST5+ and ST5- β cells 
(Figure 3.1 G-I).  Therefore, ST5 overexpression does not appear to adversely affect β cell identity.  
Having established a reliable model for inducible ST5 expression in adult β cells, we next 
sought to test the sufficiency of ST5 for driving adult β cell proliferation. We labeled β cells actively 
synthesizing DNA during S-phase by injection of BrdU 48 hours prior to sacrifice of animals. ST5 
OE mice showed a comparable percentage of BrdU+Insulin+/Insulin+ cells (Figure 3.2 A) and β cell 
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mass (Figure 3.2 B) as control mice. Furthermore, ST5 OE and control mice behaved similarly in 
glucose tolerance tests (Figure 3.2 C). These results demonstrate that ST5 overexpression alone 
does not provide increased β cell proliferation under basal metabolic states.  
 
ST5 overexpression does not augment β cell proliferation during pregnancy. 
It is well documented that both intrinsic and extrinsic signals are required to initiate and 
complete the cell cycle in β cells. Given that EGF is required for ST5 induced activation of Ras, we 
speculated that a metabolically demanding state might provide the necessary extracellular stimuli 
to unlock the mitogenic potential of ST5. EGF signaling is necessary for β cell mass expansion 
during pregnancy by activating the Ras/ERK pathway and others in response to nutrient excess 
(Hakonen et al., 2014). To determine the mitogenic potential of ST5, we employed the pregnancy 
model during which β cell proliferation increases four-fold to meet the augmented metabolic load. 
Quantification of β cell proliferation at gestational day 14.5 (GD14.5), the peak of β cell proliferation 
in pregnant mice (Parsons et al., 1992), showed a similar ratio of Ki67+Ins+/Ins+ cell numbers 
between control and ST5 OE animals (Figure 3.3 A-C). In addition, β cell mass was 
indistinguishable between the two groups despite robust ST5 overexpression (Figure 3.3 D).  
The tumor suppressor Rassf1a encodes for a negative effector of Ras, disrupting pro-
proliferative Ras/ERK signaling and preventing G1/S phase transition in normal epithelial tissues, 
leading to cell cycle arrest (Shivakumar et al., 2002; van der Weyden and Adams, 2007). Because 
Rassf1a has been shown to prevent endocrine cell expansion in knock-in mice overexpressing an 
activating mutation of Kras (Chamberlain et al., 2014), we next examined whether Rassf1a is 
induced in our pregnancy model, which may partially explain why ST5 OE does not increase β cell 
proliferation. Indeed, we found nuclear Rassf1a in a population of β cells in pregnant GD14.5 
females that is absent in non-pregnant females (Figure 3.3 E-H), suggesting that Rassf1a induction 
during pregnancy may have prevented the activation of the Ras/ERK pathway by ST5 despite the 
presence of EGF. We thus conclude that ST5 is insufficient to enhance β cell proliferation during 
pregnancy. 
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ST5 overexpression does not affect β cell proliferation in response to STZ-induced β cell damage. 
 
Next, we tested whether ST5 mediates β cell proliferation during regeneration following 
STZ-induced  cell damage. We adopted a low-dose STZ injection protocol (Tschen et al., 2009), 
which triggers overt diabetes (Ad lib glucose > 200 mg/dl) one week after the first STZ injection 
(Figure 3.4 B), indicative of severe β cell damage. ST5 OE and control mice were given BrdU in the 
drinking water for a full week following STZ injection in order to label all cell cycle entry events 
during the recovery phase under prevailing hyperglycemia (Figure 3.4 A). While increased β cell 
workload stimulated β cell replication as expected, quantification of the percentage of 
BrdU+Insulin+/total Insulin+ cells revealed that there was no difference in β cell proliferation between 
ST5 OE and control mice (Figure 3.4 C-D), suggesting that ST5 may not play an important role in 
β cell regeneration under severe injury.  
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Discussion 
In this study, we examined whether the long isoform of ST5, a Ras activator, is sufficient 
to drive β cell proliferation in adult mice during both quiescent and metabolically stressed states. 
Taking advantage of a doxycycline-inducible mouse model, we were able to temporally 
overexpress the mitogenic isoform of human ST5 in adult β cells.  
Under basal conditions, ST5 overexpression does not promote proliferation of adult β cells. 
Despite a robust upregulation of ST5 mRNA and protein levels, ST5 overexpression failed to 
stimulate the Ras/ERK pathway in the islet (data not shown). This is likely due to the lack of 
extracellular stimuli such as EGF, which are required for Ras activation by ST5. Therefore, it is not 
surprising that ST5 did not lead to increased β cell proliferation under basal metabolic conditions.  
In both the pregnancy and STZ-induced diabetes models, during which the metabolic 
demand for insulin and β cell function is heightened, ST5 overexpression does not increase the 
rate of proliferation in β cells. We were able to detect substantially stronger ERK activity in islets 
from pregnant ST5 OE mice compared to those from pregnant controls (data not shown), indicating 
that ST5 is sufficient to stimulate Ras/ERK pathway under metabolic stressful conditions. However, 
enhanced Ras/ERK signaling does not translate into an increased β cell proliferation rate.  
Several recent studies have demonstrated that negative regulators of the Ras/ERK 
signaling cascade are simultaneously activated with activation of Ras, and are capable of overriding 
the pro-proliferative effect of Ras/ERK signaling. Menin, a tumor suppressor in endocrine organs 
and inhibitor of Ras and ERK activation, has been shown to inhibit β cell proliferation and expansion 
in db/db, STZ-induced, and gestational diabetes mouse models (Karnik et al., 2007; Yang et al., 
2010a, 2010b). It is possible that the augmented activation of Ras by ST5 overexpression could 
not counteract Menin-mediated suppression of the Ras/ERK pathway in the context of STZ-induced 
diabetes.  
Rassf1a also inhibits Ras/ERK signaling and cell cycle progression, and is silenced in 
many cancers (Ahlquist et al., 2008; Burbee et al., 2001; Shivakumar et al., 2002). A recent study 
demonstrated that the constitutively active form of Kras paradoxically reduced β cell proliferation in 
embryonic and neonatal mice despite the activation of Ras/ERK signaling (Chamberlain et al., 
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2014). This is explained by the significant increase in Rassf1a activation, which counteracted the 
pro-proliferative downstream output of pERK. The same study also showed that the addition of 
Exendin-4, a potent β cell mitogen that acts on the GLP-1 incretin pathway, did not induce β cell 
proliferation unless Rassf1a activity was disrupted. This study is consistent with our finding that 
Rassf1a was activated in the pregnancy model, which may explain why overexpression of ST5 and 
increased EGF/Ras/ERK signaling did not increase β cell proliferation beyond its normal increase 
in GD14.5 females.   
Our study illustrates the challenges of identifying activators of β cell replication under 
quiescent and stressed in vivo conditions. Further investigation is needed to dissect how β cells 
integrate pro-proliferative and anti-proliferative signals in response to heightened metabolic 
demand and cell loss in order to identify effective strategies to increase β cell mass for the treatment 
of diabetes.  
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Figure 3.1 Human ST5 expression in RIP-rtTA;TRE-hST5 double transgenic mice.  
 
 
 
A. Schematic of the doxycycline-inducible ST5 overexpression (ST5 OE) mouse line. Both ST5 OE 
and single transgenic control (CON) animals were kept on doxycycline for 2 weeks prior to 
analyses.  
B-G. Immunofluorescence staining for insulin (red) and ST5 (green) in islets of 12-16 week-old 
control (B-D) and ST5 OE (E-G) animals. Expression of ST5 was limited to insulin+ cells. ST5 
overexpressing and ST5 negative cells have comparable insulin expression levels (insets in E-G).  
H-J. Pdx1 expression (red) in cells overexpressing ST5 (green). 
K. Quantitative real-time PCR analysis of human (hST5v1) and endogenous mouse ST5 (mST5) 
mRNA levels in control and ST5-overexpressing islets at 12-weeks of age. 
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Figure 3.2 ST5 overexpression does not promote β cell proliferation under basal metabolic 
conditions.  
 
A. Percentage of proliferating β cells in 12-16 week-old control and ST5 OE mice. Proliferating β 
cells were calculated by quantifying the number of BrdU+/insulin+ double positive cells over the total 
number of insulin+ cells.  
 
B. β cell mass in control and ST5 OE mice. β cell mass was derived from the total pancreas weight 
multiplied by the percentage of β cell area (as detected by insulin positive staining) relative to the 
whole pancreatic area.  
 
C. Glucose clearance traces of a glucose tolerance test performed on 12-16 week-old control and 
ST5 OE males. 
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Figure 3.3 Increased mitogenic stimuli during pregnancy do not induce increased β cell 
proliferation in ST5 OE mice. 
 
A-B. Immunofluorescence staining for Ki67 (red) and insulin (green) from gestational day (GD) 14.5 
control and ST5 OE females. 
C. β-cell proliferation in GD 14.5 control and ST5 OE females.  
D. β-cell mass in GD 14.5 control and ST5 OE females.  
E-H. Immunofluorescence staining for Rassf1a (cyan) and insulin (red) from non-pregnant and 
GD14.5 control females. β cells with nuclear Rassf1a are indicated with white arrows. 
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Figure 3.4 ST5 overexpression does not induce β cell proliferation in response to STZ-
induced β cell damage.  
 
 
A. Schematic of experimental timeline. 12-16 week-old control and ST5 OE mice were maintained 
on doxycycline throughout the course of the experiment. The mice were injected with STZ the first 
4 days of the study. During the second week, BrdU was added to the Dox+ drinking water.                                                
B. Glucose levels of control and ST5 OE mice during and after STZ induction. By the fifth day, the 
mice were hyperglycemic (Ad lib glucose > 200 mg/dl), indicating significant β cell loss.                                  
C. Representative insulin (red), BrdU (cyan), and ST5 (green) immunofluorescence staining in a 
control and ST5 OE islet.  
D. β cell proliferation in control and ST5 OE males.   
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CHAPTER FOUR 
 
Targeted epimutation at the Imprinting Control Region 2 
induces human β cell replication 
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Abstract 
 
 The loss of insulin-secreting β cells is characteristic among Type I and Type II diabetes. 
Stimulating proliferation to expand sources of β cells for transplantation remains a challenge 
because adult β cells do not proliferate readily. The cell cycle inhibitor p57 has been shown to 
control cell division in human β cells. Expression of p57 is regulated by the DNA methylation status 
of the Imprinting Control Region 2 (ICR2), which is commonly hypomethylated in Beckwith 
Wiedemann-Syndrome patients who exhibit massive β cell proliferation. We hypothesized that 
targeted demethylation of the ICR2 using a transcription activator-like effector protein fused to the 
catalytic domain of TET1 (ICR2-TET1) would repress p57 expression and promote cell proliferation. 
We report here that overexpression of ICR2-TET1 in human fibroblasts reduces p57 expression 
levels and increases proliferation. Furthermore, human islets overexpressing ICR2-TET1 exhibit 
repression of p57 with concomitant upregulation of Ki-67 while maintaining glucose-sensing 
functionality. When transplanted into diabetic, immunodeficient mice, the epigenetically edited 
islets show increased β cell replication compared to control islets. These findings demonstrate that 
epigenetic editing is a promising tool for inducing β cell proliferation, which may one day alleviate 
the scarcity of transplantable β cells for the treatment of diabetes. 
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Introduction 
In 2014, a staggering 422 million people worldwide lived with diabetes (CDC, 2017b). While 
patients with Type I or severe forms of Type II Diabetes are able to manage extreme glucose 
excursions by administering insulin shortly before a meal, only β cell replacement therapy through 
transplantation of healthy pancreatic islets obtained from carefully screened deceased organ 
donors has been demonstrated to provide long-term diabetes reversal without the need of insulin 
injections (Hering et al., 2016; Rickels et al., 2016). However, the universal applicability of β cell 
replacement therapy is limited by the availability of transplantable donor islets. As a result, there is 
a concerted effort to produce functionally mature β cells from embryonic stem cells and induced 
pluripotent stem cells, or to identify strategies to enhance β cell proliferation (Millman et al., 2016; 
Wang et al., 2015b). 
Although inducing β cell proliferation would appear to be a straightforward approach, it is 
severely limited by the fact that the proliferative capacity of human β cells declines dramatically 
after early childhood (Maedler et al., 2006; Wang et al., 2016a). This correlates with an age-related 
accumulation of the senescence effector p16 that induces cell cycle arrest in β cells (Köhler et al., 
2011). Strikingly, the overgrowth disorder Beckwith Wiedemann-Syndrome (BWS) is characterized 
by an expansion of β cell mass - among other tissue types - that is associated with decreased 
protein levels of the cell cycle inhibitor p57 (Kalish et al., 2016; Weksberg et al., 2010), a recognized 
negative regulator of β cell replication (Avrahami et al., 2014; Calvello et al., 2013; Ueberberg et 
al., 2016). 
        The cell cycle inhibitor p57 is the protein product of the CDKN1C gene, which is imprinted 
and regulated by the DNA methylation status of the nearby imprinting control region 2 (ICR2). The 
ICR2 is a CpG-dense region located on chromosome 11p15.5 that is hypomethylated on the 
paternal allele, and hypermethylated on the maternal allele (Diaz-Meyer et al., 2003). This 
asymmetrical methylation signature is linked to preferential expression of CDKN1C from the 
maternal allele through molecular mechanisms that are still not well understood. In the majority of 
patients with BWS, the ICR2 is hypomethylated on both alleles (Calvello et al., 2013; Diaz-Meyer 
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et al., 2003; Weksberg et al., 2010), correlating with de-activation of CDKN1C and an increase in 
proliferation of β cells. 
       By mimicking the molecular alterations observed in BWS via transcription activator-like 
effector (TALE)-epigenome editing (Figure 4.1 A), we were able to target and demethylate the ICR2 
in β cells of human islets. We show in this proof-of-principle study that targeted epigenetic editing 
can be harnessed to induce β cell proliferation and model critical aspects of human imprinting 
disorders. 
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Results 
 
A TALE-TET1 effector causes specific demethylation of the ICR2 at the CDKN1C locus. 
TALE proteins are commonly utilized for epigenome editing due to their customizable yet 
highly specific DNA-recognition domain and compatibility with numerous chromatin modifiers 
(Amabile et al., 2016; Mussolino et al., 2014). Indeed, a prior study demonstrated the high 
specificity and limited off-target effects of TALE proteins fused to the catalytic domain of 
methylcytosine dioxygenase TET1 (Maeder et al., 2013), which facilitates the passive and active 
demethylation of methylated CpGs. We designed a TALE-TET1 fusion protein targeting the ICR2 
(ICR2-TET1) at chr11:2,720,607-2,720,625. As controls, we engineered a fusion protein with an 
identical TALE DNA-binding domain ligated to a mutated, enzymatically dead TET1 protein (ICR2-
TET1dead), and an untethered TET1 catalytic domain (TET1-cd). By performing targeted bisulfite 
sequencing in sorted HEK293T cells (Bernstein et al., 2015), we found that the ICR2-TET1 protein 
induced demethylation at its binding site in the ICR2 (Figure 4.1 B), demonstrating local specificity 
of the epimutation achieved. Importantly, methylation at regions 2 and 3 of the ICR2, including the 
KCNQ1OT1 promoter, was not changed by the ICR2-TET1 protein. Furthermore, the untethered 
TET1-cd had no effect on DNA methylation at the targeted locus. These results establish that the 
ICR2-targeting TALE-TET1 protein is functional and a suitable tool for investigating the relationship 
between the ICR2 methylation status, p57 expression, and proliferative capacity of epigenetically 
edited cells.  
 
Targeted demethylation of the ICR2 decreases expression of p57 in cell lines.  
Next, we assessed whether or not targeted demethylation of the ICR2 reduces the 
expression of the cell cycle inhibitor CDKN1C. In sorted HEK293T, there was a significant 10-fold 
reduction in CDKN1C expression levels in the ICR2-TET1 group compared to the ICR2-TET1dead 
control (Figure 4.2), confirming that gene silencing resulted from TALE-TET1 induced 
demethylation and not through simple steric hindrance by binding of the TALE fusion protein itself.  
Human fibroblasts transduced with a lentivirus overexpressing ICR2-TET1 also exhibited 
a decrease in expression and protein levels of p57 when compared to the ICR2-TET1dead control 
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(Figure 4.1 C). In addition to the observed downregulation of p57, we also detected activation of 
MKI67 encoding Ki-67, a marker of proliferation, in transduced human fibroblasts (Figure 4.1 C). 
These results demonstrate a causal relationship between the DNA methylation status of the ICR2 
and CDKN1C gene expression. 
  The mechanism by which the methylation status of the ICR2 regulates CDKN1C 
expression is unclear. Several studies have suggested that the long non-coding RNA KCNQ1OT1, 
which is transcriptionally active when the ICR2 is hypomethylated, silences CDKN1C in cis (Green 
et al., 2007; Mancini-Dinardo et al., 2006). Although we observed a slight increase in expression 
levels of KCNQ1OT1 in both transfected HEK293T cells and transduced fibroblasts (Figure 4.1 C, 
Figure 4.2), we did not find any significant increase in bi-allelic expression of KCNQ1OT1 in 
response to ICR2 demethylation by DNA-RNA FISH (Figure 4.3), suggesting that deactivation of 
CDKN1C is mediated by a mechanism independent of the in cis function of KCNQ1OT1 (Fitzpatrick 
et al., 2007; Kanduri et al., 2002).  
 
Demethylation of the ICR2 increases proliferation in human fibroblasts. 
Having established that targeted demethylation of the ICR2 causes inactivation of p57 and 
increased expression of Ki-67 in human fibroblasts, we wanted to evaluate the phenotypic outcome 
of TALE-TET1-induced demethylation of the ICR2. We performed an in vitro proliferation assay by 
quantifying incorporation of the thymidine analog EdU into actively synthesizing DNA strands of 
human fibroblasts that have been transduced by the ICR2-TET1 or ICR2-TET1dead control 
lentivirus.  We found a significant increase in the percentage of EdU positive cells in the ICR2-
TET1 treated fibroblasts compared with ICR2-TET1dead controls (Figure 4.1 D), confirming that our 
strategy to generate an epimutation at the ICR2 can indeed induce cell proliferation. 
 
 
p57 levels are reduced in epigenetically edited human pancreatic β cells.  
Pursuing our ultimate interest in the applicability of epigenetic editing by ICR2-TET1 
towards increasing β cell mass, we employed our TALE-TET1 strategy on human islets obtained 
from non-diabetic, non-obese deceased organ donors. Because of low-efficiency of transduction 
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with lentiviral vectors (data not shown), we transferred our ICR2-TET1 and ICR2-TET1dead constructs 
into adenoviral vectors. Consistent with our observations in human fibroblasts, islets transduced 
with an adenovirus overexpressing ICR2-TET1 displayed decreased expression levels of CDKN1C 
(Figure 4.4 A). Considering that the adenovirus transduced only a subset of the islet cells (Figure 
4.5), the actual decrease in CDKN1C expression in the transduced β cells is likely underestimated 
here. Importantly, several independent transcriptomic studies had reported that CDKN1C is 
expressed primarily in β cells compared to other islet endocrine cell types (Bramswig et al., 2013; 
Muraro et al., 2016; Wang et al., 2016b), suggesting that the decrease in CDKN1C expression 
resulting from ICR2-TET1 overexpression primarily occurred in β cells. Donor-to-donor variability 
in CDKN1C deactivation can be attributed to variability in transduction efficiency, where on average 
only 20-40% of β cells were successfully transduced. Despite variation between the individual 
donors assayed, there was a significant decrease in CDKN1C transcript levels in the ICR2-TET1 
treated islets when all donors were analyzed collectively (p < 0.05) (Figure 4.4 B). Decreased p57 
protein levels were further verified through immunocytochemistry staining of transduced compared 
with non-transduced β cells (Figure 4.4 C). Notably, GFP+ β cells transduced with Ad.ICR2-TET1dead 
virus maintained p57 levels.  
 
Epigenetically edited β cells retain glucose-sensing functionality.  
 We next wanted to determine whether p57 deactivation impacted β cell function. We first 
performed whole islet perifusion to determine differences in glucose-stimulated insulin secretion 
(GSIS) between Ad.ICR2-TET1dead and Ad.ICR2-TET1 transduced islets. We found that GSIS was 
not impaired in Ad.ICR2-TET1 transduced islets compared to Ad.ICR2-TET1dead controls (Figure 4.6 
A). However, only a subset of β cells were transduced in the whole islet, necessitating the need for 
an additional technique to assess functionality of the transduced β cells specifically. We measured 
single-cell intracellular calcium concentrations as a surrogate for insulin secretion in transduced β 
cells by using Fura-2 as a calcium indicator. Basal [Ca2+]i as well as calcium response to high 
glucose stimulation were similar between GFP+, Ad.ICR2-TET1 transduced β cells and GFP+, 
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Ad.ICR2-TET1dead control cells (Figure 4.6 B). Together, these results demonstrate that targeted 
demethylation of the ICR2 does not negatively impact β cell function. 
 
Targeted demethylation of the ICR2 leads to increased replication of β cells. 
 After verifying that epigenetically edited β cells displayed normal glucose-sensing behavior, 
we next assessed the effect of targeted ICR2 demethylation on β cell replication. In addition to 
decreased CDKN1C transcript levels, ICR2-TET1 treated human islets exhibited increased 
expression of the proliferation marker MKI67, which was significantly anti-correlated with CDKN1C 
transcript levels (Figure 4.7 A).  We were also able to detect Ki-67 protein in transduced β cells, as 
well as quantify an increase in expression of several cell cycle genes controlling the G2/M transition 
(Figure 4.8).  
In order to study the long-term effect of TALE-TET1-induced epimutation on β cell 
proliferation, we utilized the immuno-deficient NOD-scid IL2rγnull (NSG) mouse model rendered 
diabetic with treatment of streptozotocin (Figure 4.7 B). To control for the variability of mitogenic 
stimuli provided by the host, each diabetic NSG mouse was transplanted simultaneously with 100 
Ad.ICR2-TET1 and Ad.ICR2-TET1dead transduced islets (placed in opposite subcutaneous pockets). 
After transplantation, mice were administered BrdU in the drinking water for three weeks in order 
to label every cell that entered S-phase during this time frame. The transplanted islets were able to 
correct the hyperglycemic glucose levels of the NSG mice, indicating that they remain functional 
(Figure 4.9). After 3 weeks, the islet xenografts were harvested, processed for paraffin sectioning, 
and stained for C-peptide and BrdU to identify β cells and cells that replicated their DNA, 
respectively. Strikingly, we observed an increase in the percentage of BrdU-positive β cells in the 
islet fraction that had received the ICR2-TET1 compared to the ICR2-TET1dead control in four out of 
the five donors that underwent the transplant study (Figure 4.7 C,D). Furthermore, we detected 
BrdU-positive doublets, which suggests that the transduced β cells are capable of completing 
mitosis (Figure 4.7 E). These results demonstrate the applicability of epigenetic editing for 
promoting β cell replication. It is notable that targeted demethylation of the ICR2 also led to an 
increase in proliferation of alpha cells, which express CDKN1C at lower levels than β cells (Figure 
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4.10). Thus, the development of an adenoviral or AAV system specifically targeting β cells will be 
necessary to move epimutation of the ICR2 using TALE-TET1 closer to therapeutic applications. 
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Discussion 
We demonstrate that epigenetic editing can be applied to promote replication in human 
pancreatic β cells. We successfully demonstrate that targeted demethylation of the ICR2 directly 
results in the downregulation of p57, aligning with the underlying epigenetic cause of BWS. In β 
cells, this epimutation causes increased Ki-67 expression as well as increased cell cycle entry as 
detected by BrdU incorporation in the xenografts of transplanted NSG mice.  
 Epigenetic editing holds great therapeutic potential due to its effectiveness at 
reprogramming stable epigenetic marks to modulate expression of disease-related genes. Already, 
several studies have demonstrated the promise of epigenetic editing in targeting genes involved in 
various cancers and neurological disorders (Falahi et al., 2013; Garcia-Bloj et al., 2016; Heller et 
al., 2014). In the context of stimulating β cell replication, targeting p57 through epigenetic editing is 
an attractive strategy for several reasons. First, p57 is difficult to inhibit pharmacologically due to 
its nuclear localization, necessitating intervention at the gene regulation level. Secondly, the DNA 
methylation signature of the epigenetically edited parent cell is inherited by the daughter cells after 
cell division, which suggests that CDKN1C will remain silenced after multiple rounds of cell division. 
However, additional studies are needed to investigate how long the induced epimutation and p57 
deactivation can be maintained, and to evaluate the risk for hyperinsulinism from continuous β cell 
expansion. Our data suggest that the epigenetically edited β cells have functional KATP channels 
because they do not have persistent membrane depolarization, and thus should be responsive to 
diazoxide to attenuate insulin secretion if needed. Altogether, our results for using epigenetic 
editing to promote β cell replication is an encouraging starting point towards increasing supply of 
transplantable β cells for diabetic patients. 
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Figure 4.1 Targeted demethylation of the ICR2 at the CDKN1C/p57 locus causes increased 
proliferation of human fibroblasts.  
 
(A) Schematic of the imprinted chr11p15.5 locus. The ICR2 is methylated (depicted by black circles) 
at the promoter of the lncRNA KCNQ1OT1 on the maternal allele, and correlates with maternal 
allele-specific expression of CDKN1C. A TALE-TET1 fusion protein was designed to target the 
ICR2 and remove the methylCpGs at the ICR2 in order to deactivate CDKN1C and increase cell 
proliferation.  
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(B) Three regions within the ICR2 were amplified for methylation analysis by targeted bisulfite 
sequencing. Percent CpG methylation at three regions of the ICR2 are shown (n=3 for each 
condition). Average CpG methylation in Region1 was analyzed by two-tailed t-test (*, p<0.05). 
 
(C) p57 mRNA and protein levels in fibroblasts overexpressing ICR2-TET1dead or ICR2-TET1 (n=3 
for each condition; *, p<0.05, one-tailed t-test).  
 
(D) EdU incorporation in fibroblasts 72 hours after transduction with the ICR2-TET1dead or ICR2-
TET1 lentivirus (n=5 for each condition; **, p<0.01, two-tailed t-test). 
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Figure 4.2 Gene expression in sorted HEK293T cells.  
 
Changes in gene expression in HEK293T cells overexpressing ICR2-TET1dead or ICR2-TET1  
(*, p<0.05; **, p<0.01). 
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Figure 4.3 RNA-DNA FISH for KCNQ1OT1 in transduced fibroblasts.  
 
 
 
(A) DNA and RNA fluorescent in situ hybridization of the chr11p15.5 genomic locus (yellow) and 
nascent KCNQ1OT1 mRNA (magenta) in sorted fibroblasts. The nucleus (gray) containing bi-allelic 
expression of KCNQ1OT1 is indicated by the white arrow.  
 
(B) Quantification of nuclei containing zero, one (mono-allelic), or two (bi-allelic) KCNQ1OT1 RNA 
FISH spots (n=100 for both ICR2-TET1dead and ICR2-TET1 groups). 
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Figure 4.4 ICR2-TET1 deactivates p57 in human  β cells. 
 
(A) CDKN1C mRNA expression in islets transduced for 72 hours with the ICR2-TET1dead or ICR2-
TET1 adenovirus. Islets were obtained from seven non-diabetic, non-obese deceased organ 
donors.  
 
(B) CDKN1C mRNA expression in islets grouped by adenoviral treatment. Each point represents 
the relative expression of CDKN1C from one of the donors from Figure 2A (n=7 for each condition; 
*, p<0.02, Wilcoxon matched-pairs signed rank test).  
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(C) Immunocytochemistry staining of transduced β cells. White arrows indicate transduced GFP+ β 
cells, while purple arrows indicate untransduced controls. Unlike the Ad.ICR2-TET1dead transduced 
β cells, Ad.ICR2-TET1 transduced β cells stained weakly for p57 (scale bar: 50 um). 
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Figure 4.5 Transduction efficiency in human  β cells.  
 
Human islet samples were dispersed and antibody labeled for analysis by flow cytometry. 
Sequential gating was used to exclude doublets and cell clusters (subpanel 1), dead cells (subpanel 
2), non-cell events (subpanel 3), and acinar / duct / endothelial / alpha cells (subpanel 4). GFP+ 
cells were gated on the β cell population. 
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Figure 4.6 Epigenetically edited  β cells retain glucose-sensing behavior.  
 
 
(A) Glucose stimulated insulin secretion in Ad.ICR2-TET1dead and Ad.ICR2-TET1 transduced islets.  
 
(B) [Ca2+]i levels in Ad.ICR2-TET1dead GFP+ (n=5) and Ad.ICR2-TET1 GFP+ (n=3) β cells in response 
to 3 mM glucose, 16.7 mM glucose, and 30 mM KCl stimulation.  
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Figure 4.7 Targeted epimutation at the ICR2 induces human  β cell replication.  
 
(A) Expression of CDKN1C mRNA is significantly anticorrelated with mRNA expression levels of 
the proliferation marker MKI67 in islets transduced with Ad.ICR2-TET1. mRNA levels were 
normalized to HPRT1. Each point represents a single donor. 
 
(B) Schematic of subcutaneous transplantation of transduced human islets in diabetic NSG mice. 
For each donor, 100 islets transduced with the ICR2-TET1dead or ICR2-TET1 adenovirus were 
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transplanted in the left and right subcutaneous abdominal incision, respectively. Mice were 
administered BrdU via the drinking water for 3 weeks before the grafts were harvested.  
 
(C) Example of an islet transduced with Ad.ICR2-TET1 with three BrdU+ β cells. For each donor 
and treatment, 800-2000 C-peptide+ cells were counted (scale bar: 50 ⎧m). 
 
(D) Percentage of BrdU+ β cells in sectioned xenografts three weeks after transplant. Each pair of 
points represents an individual donor (*, p<0.05, ratio paired t-test).  
 
(E) BrdU/C-peptide double-positive doublets, indicated by the white arrows, in Ad.ICR2-TET1 
transduced xenografts. 
 
  
79 
 
Figure 4.8 Additional evidence for replication in  β cells.  
 
 
(A) Transduced islets were enzymatically dispersed on a coverslip and immunolabeled for C-
peptide, Ki-67, GFP, and DAPI. Scale bar: 10 μm.  
 
(B) mRNA levels of G2/M transition genes in transduced whole islets obtained from 3 non-obese, 
non-diabetic donors. mRNA levels were normalized to HPRT1.  
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Figure 4.9 Blood glucose levels of streptozotocin-treated NSG mice after human islet 
transplantation.  
 
 
NSG mice were fasted overnight before STZ injection at a dose of 200 mg/kg of body weight. After 
3 days, mice were subcutaneously transplanted with 0 islets or 200 total islets. Blood glucose was 
monitored during the duration of the study (n = 4 for each group).  
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Figure 4.10 Targeted demethylation of the ICR2 induces α cell proliferation.  
 
(A) CDKN1C mRNA levels from single cell RNA-seq data (**, p<0.01 using Mann-Whitney test).  
 
(B) Example of a xenograft section immunolabeled for glucagon and BrdU. BrdU+ alpha cells are 
indicated with white arrows. Scale bar: 50 um.  
 
(C) Percentage of BrdU+ alpha cells in sectioned xenografts. Each pair of points represents an 
individual donor. P-value was calculated using the ratio paired t-test after testing for normality using 
the Shapiro-Wilk test (*, p<0.05).  
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CHAPTER FIVE 
 
Discussion and future directions: 
The development of targeted β cell therapies 
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Summary 
 
Generating additional sources of β cells for cell replacement therapy is coming closer to 
reality for severely diabetic patients. In particular, promoting replication of pre-existing β cells is 
more feasible due to advancements in targeted genome and epigenome editing, which can activate 
or deactivate cell cycle targets in a locus-specific manner. The explosion of recent targeted 
(epi)genome editing technologies has greatly increased potential genetic and epigenetic therapy 
solutions for diabetes and many other human diseases. However, the most challenging step in 
creating any viable therapy is the identification of a suitable biological target for disease 
intervention. Targets derived from the genetic elucidation of human disease are promising. This 
latter point is emphasized by my work on successfully inducing human β cell proliferation by 
mimicking the epimutation found in Beckwith Wiedemann Syndrome patients, who are 
characterized by profound β cell hyperplasia. Here, I will summarize a few recent developments 
that hold promise for moving this approach towards clinical applications. 
 
Identifying a suitable target for inducing human β cell proliferation 
 While they are occasionally successful at identifying druggable therapeutic targets, mouse 
models do not always recapitulate the processes that are dysregulated in human physiology and 
disease. Adaptive β cell proliferation may be such a case. Although studies in mice demonstrate 
that pregnancy, diet-induced, and streptozotocin-induced diabetes promote β cell proliferation, no 
clear evidence shows that these processes take place in adult humans. Histological analyses of 
lean, obese, and type 2 diabetic human pancreatic sections have confirmed that there are 
differences in β cell mass between the three groups (Linnemann et al., 2014). β cell mass is larger 
in non-diabetic obese samples compared to lean non-diabetic samples, and is lower in both lean 
and obese type 2 diabetic samples compared to lean non-diabetic samples. However, it is unclear 
whether some individuals are merely born with higher β cell mass and are thus resistant to diabetes, 
or that diabetes-resistant individuals can successfully compensate for insulin resistance through 
adaptive β cell proliferation, or that β cells in diabetic patients are more prone to apoptosis 
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compared with non-diabetic individuals. Histological analyses using proliferation markers Ki-67 and 
proliferating cell nuclear antigen (PCNA) have produced conflicting results. Some studies 
concluded that there were no differences in β cell replication between lean, obese, and type 2 
diabetic individuals (Butler et al., 2003; Saisho et al., 2013), while others found that there were 
increased rates in obese individuals and decreased rates in type 2 diabetic samples (Hanley et al., 
2010). Altogether, generalizing pro-proliferative processes that regulate β cell replication in mice 
towards human biology may be unwise. 
Because of the discrepancies between mouse and human studies, many academic and 
pharmaceutical groups have turned to human genetics, whether through genome-wide association 
or Mendelian inheritance studies, to identify relevant therapeutic targets for human disease. For 
the second part of my thesis, I mimicked the epigenetic cause of Beckwith-Wiedemann Syndrome, 
a naturally occurring human disease characterized by β cell proliferation. I have demonstrated that 
targeted demethylation of the Imprinting Control Region 2 at chromosomal region 11p15.5 was 
capable of inducing β cell replication by repressing expression of CDKN1C/p57. Delivering the 
engineered ICR2-targeting TALE-TET1 fusion protein to pancreatic islets ex vivo was capable of 
promoting β cell proliferation when transplanted into diabetic immunodeficient mice. These results 
have significant implications for increasing sources of transplantable β cells for islet replacement 
therapy, and for developing a viral-mediated gene therapy strategy to preemptively increase 
endogenous functional β cell mass, thereby preventing development of diabetes.  
 However, there are several outstanding questions that must be addressed with future 
studies in order to determine the feasibility of using the ICR2-targeting TALE-TET1 protein for 
clinical applications. How stable is TALE-TET1-induced epimutation in transduced β cells? If the 
epigenetically edited β cells continuously proliferate, will patients be at risk for hyperinsulinemia-
induced hypoglycemia or cancer development? How can the TALE-TET1 system be targeted 
specifically to β cells in order to minimize off-target effects in other endocrine cell types? I have 
highlighted future directions to address each of these points below.  
 
 
85 
 
(1) How stable is TALE-TET1-induced epimutation in proliferating β cells? 
 In my β cell studies described in Chapter 4, the TALE-TET1 gene was constitutively 
expressed downstream of a CMV promoter in a recombinant adenoviral vector. Due to the low 
replication rate of β cells and high multiplicity of infection (MOI) required to transduce β cells (MOI 
= 300 viral particles for 1 cell), expression of the TALE-TET1 transgene can persist for an indefinite 
period of time. The prolonged expression of TALE-TET1 would presumably oxidize any cytosines 
that have reverted back to methyl-cytosines. Thus, our current system cannot answer how long the 
induced demethylation of the ICR2 can be stably maintained.  
In order to address this question, a doxycycline inducible TALE-TET1 system needs to be 
developed, allowing for the precise activation and deactivation of transgene expression. One would 
have to generate a new adenoviral vector co-expressing the TALE-TET1 transgene under the 
control of the tetracycline response elements (TRE), and the reverse tetracycline transactivator 
(rtTA) gene under the control of a constitutively active promoter. Only under the presence of 
doxycycline will rtTA bind to TRE to drive expression of the TALE-TET1. One can analyze the 
methylation profile of the ICR2 and expression of CDKN1C/p57 at different time points post 
transduction and doxycycline treatment.  
 
(2) How would you address the risk for hyperinsulinemia-induced hypoglycemia and cancer?  
 It is certainly possible that indefinite β cell proliferation induced by p57 deactivat ion can 
result in hypoglycemia in patients transplanted with epigenetically edited β cells. I have 
demonstrated through single cell Ca2+ imaging that Ad.ICR2-TET1-transduced β cells have normal 
glucose-sensing behavior; they are unresponsive to low glucose and have increased calcium influx 
in response to high glucose. Furthermore, the transduced β cells seem to retain functionality of the 
inward rectifying KATP channels. β cells transduced with Ad.ICR2-TET1 do not have persistent 
membrane depolarization and elevated intracellular Ca2+ under low glucose conditions, signifying 
that the KATP channels remain functional and capable of facilitating membrane repolarization. 
Therefore, transplant recipients that develop hypoglycemia theoretically should be responsive to 
diazoxide, a KATP channel activator that inhibits membrane depolarization and attenuates insulin 
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secretion. It is notable that pediatric patients with congenital hyperinsulinism and focal β cell 
hyperplasia commonly have chromosomal deletions in the maternal chromosomal region 11p15 
(which, in addition to CDKN1C and the ICR1 and ICR2 imprinted clusters, contains the KATP subunit 
genes KCNJ11 and ABCC8) along with paternally inherited mutations in the KCNJ11 and/or 
ABCC8 genes (Henquin et al., 2011; Suchi et al., 2006). These inactivating mutations lead to hyper-
insulin secretion due to elevated intracellular Ca2+ levels. However, targeted demethylation of the 
ICR2 alone has not been reported to affect transcriptional regulation of KCNJ11 and ABCC8.  
 Insulinomas that develop from β cell hyperplasia are very small tumors that rarely 
metastasize, and thus I predict that TALE-TET1-mediated deactivation of p57 will not result in the 
development of cancer. However, in order to prevent insulinoma and cancer development, one 
could encapsulate the epigenetically edited β cells in a retrievable implantation device prior to 
transplantation. Any evidence of hyperinsulinemic hypoglycemia or cancer development could be 
addressed by removing the implantation device (Agulnick et al., 2015).  
 
(3) How can the TALE-TET1 system be targeted specifically to β cells in order to minimize off-target 
effects in other endocrine cell types? 
 While my current adenoviral system does not target the β cells specifically, there are certain 
developments in viral- (and non-viral) mediated targeted β cell therapy field that can be applied to 
the TALE-TET1 system in the near future. Briefly, major advancements in generating a β cell-
targeting AAV will allow for targeted delivery of the TALE-TET1 transgene. The capsid proteins of 
the AAV have been genetically modified to have minimized tropism for the liver while increased 
tropism for the human pancreas. Furthermore, this AAV contains a β cell-specific promoter and 
regulatory elements that promote expression of the transgene specifically in the β cells and not 
alpha cells or other islet cell type. 
 
My work on TALE-TET1 induced β cell replication adds to the growing body of evidence 
that targeted epigenetic editing strategies carry great potential for clinical applications. Targeted 
epigenetic editing of a specific locus would undoubtedly minimize global epigenetic changes as 
seen with treatment using small molecule inhibitors of epigenetic modifier enzymes (such as 
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Azacitidine-mediated inhibition of DNMTs). Additionally, targeted epigenetic effectors can be 
delivered by viral vectors, which can be engineered to selectively transduce specific cell types. For 
this reason, viral-mediated (epi)gene therapy could hold particular promise for the selective 
treatment of β cells, if a suitable viral or non-viral vector could be engineered.  Below, I expand on 
current developing technologies that will hopefully lead to improved targeted therapies for β cell 
regeneration.  
 
The development of β cell-targeting viral vectors  
 
 Recombinant adenoviruses, such as the one used for the TALE-TET1 studies in my thesis 
work, possess many attractive features for therapeutic purposes. They have a relatively large 
double stranded DNA (dsDNA) genome and thus can accommodate large transgenes up to ~8 kb 
in size (Lee et al., 2017). Unlike retroviral and lentiviral vectors, adenoviruses are capable of 
transducing both dividing and non-dividing cells, allowing targeting of differentiated cell types such 
as neurons and β cells. Furthermore, the adenoviral genome does not stably integrate into the host 
cell’s genome, minimizing risk for malignant cell transformation due to insertional mutagenesis (a 
risk carried by retroviral and lentiviral vectors) (Schambach et al., 2013). The recombinant 
adenoviral serotypes Ad2 and Ad5 are commonly used for in vitro studies due to very broad tissue 
tropism, transducing virtually any cell population. Transduction efficiency is attributed by the 
adhesion of the adenoviral fiber tip to the coxsackievirus adenovirus receptor (CAR), and the 
binding of the adenoviral penton base to cell surface αv integrins, triggering clathrin-mediated 
endocytosis of the viral particle. Expression of CAR and αv integrins is prevalent on almost all cell 
types, contributing to the wide tissue tropism of Ad2 and Ad5 adenoviruses (Lee et al., 2017).  
Because of the high transduction efficiency, islet biologists have used Ad5 adenovirus to 
overexpress genes in cultured islets isolated from rodent and deceased human donors. In order to 
achieve β cell-specific gene delivery, an Ad5 adenovirus containing the rat insulin promoter has 
been generated by multiple labs (Bone et al., 2012). However, while demonstrating β cell-enriched 
transduction in rodent islets (Bone et al., 2012; Hayes et al., 2016), unpublished work in our lab 
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suggests that the rat insulin promoter drives leaky expression of the transgene in all human 
pancreatic endocrine cell types.  
In reality, the human clinical application of adenoviral-mediated targeted β cell gene 
therapy is unlikely. Due to very high liver tropism, adenovirus injection can cause severe liver 
toxicity in human patients (Keeler et al., 2017; Raper et al., 2003). Furthermore, recombinant 
adenoviruses elicit a massive innate immune response, which was observed in early gene therapy 
trials. Both of these serious adverse reactions contributed to the unfortunate death of a patient 
enrolled in an adenoviral gene therapy clinical trial led by the University of Pennsylvania in 1999 
(Stolberg, 1999).  
To improve the safety profile of adenoviruses, several genetic and chemical modifications 
were made to the adenoviral capsid which decreased liver tropism (Capasso et al., 2014). For 
instance, coating adenoviral particles with non-covalent polymers, as well as mutating either the 
adenoviral fiber or penton base to impair binding to CAR receptors or αv integrins, have 
successfully de-targeted the liver (Leggiero et al., 2013; Zhao et al., 2011). Despite progress in 
improving recombinant adenoviral-mediated gene delivery, there have been no reports on 
successfully engineering adenoviruses to selectively target pancreatic β cells in humans.  
 
Creating a β cell-targeting adeno-associated viruses  
 Recently, recombinant adeno-associated viruses (AAV) have replaced adenoviruses as 
the viral vector of choice for gene therapy. The most important advantage of employing 
recombinant AAVs is their low immunogenic profile. In fact, wild-type AAV is not known to cause 
any serious human disease, and infection triggers only a mild and transient immune response 
(Colella et al., 2018). Recombinant AAVs share some features with recombinant adenoviruses. 
They are non-enveloped, have the ability to transduce both dividing and non-dividing cells, and 
their genome remains episomal (i.e. - does not integrate into host genome). However, recombinant 
AAVs differ in that their genome consists of single-stranded DNA that has a much smaller 
packaging capacity than recombinant adenoviruses; thus, recombinant AAVs are capable of 
expressing transgenes only up to ~4.5 kb. There are currently dozens of ongoing clinical trials using 
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AAV-mediated gene transfer for the therapeutic treatment of different human genetic diseases 
(Naso et al., 2017). In late 2017, the FDA approved the first ever gene therapy for the correction of 
a genetic disease. The one-time injection of Luxturna, a recombinant AAV expressing wild-type 
RPE65 that was developed by Spark Therapeutics and the Children’s Hospital of Philadelphia, 
successfully demonstrated efficacy and safety for the treatment of retinal dystrophy associated with 
mutations in RPE65 (Ledford, 2017). This landmark approval emphasizes the feasibility of using 
viral vectors for targeted clinical applications.  
 Recombinant AAV serotypes 1, 2, 5, 6, 8, and 9 are commonly used in gene therapy 
experimental studies due to their high transduction efficiency and well characterized tissue tropisms 
(Naso et al., 2017). Comparative studies in mice determined that retrograde pancreatic intraductal 
delivery of AAV6, AAV8, and AAV9, all containing a GFP reporter downstream of a ubiquitous CAG 
promoter, mediated long-term and efficient transduction in β cells, acinar cells, and liver (Jimenez 
et al., 2011). Interestingly, all of adenoviruses had limited transduction efficiency in mouse alpha 
cells. However, systemic injection of the adenoviruses resulted in poor transduction of the pancreas 
and high transduction of the liver, suggesting that local injection through the pancreatic duct is 
critical for targeting the pancreas. Furthermore, replacing the ubiquitous CAG reporter with the rat 
insulin promoter enhanced β cell selectivity while minimizing transduction efficiency in the exocrine 
pancreas, demonstrating the importance of using cell-specific promoters to improve cell-type 
tropism (Jimenez et al., 2011).  
High liver tropism remains a major challenge for the development of a pancreatic β cell-
targeting gene therapy. While convenient for developing gene therapy strategies for 
reprogramming hepatocytes into insulin-secreting β-like cells (Wang et al., 2007), broad liver 
tropism necessitates invasive surgical procedures in order to locally deliver the AAV directly to the 
pancreas in mice. Furthermore, a recent report on a preclinical gene therapy study for spinal 
muscular atrophy described high liver toxicity requiring euthanasia in several nonhuman primates 
and piglets (Hinderer et al., 2018). Liver toxicity attributed by broad liver tropism in many AAV 
serotypes is a serious issue that must be addressed in order to advance preclinical and clinical 
gene therapy trials.  
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 In response, several groups have identified strategies to engineer liver de-targeted AAVs 
by modifying the viral capsid surface. While a novel strain of a β cell-targeting, liver-detargeting 
AAV remains in development, successful attempts to generate AAVs that target other tissues with 
minimized tropism for the liver have been made/exist (Pulicherla et al., 2011). AAV capsid proteins 
interact with cell surface carbohydrates (galactose1, heparin sulfate, and sialic acid) and 
transmembrane receptors (platelet derived growth factor receptor, hepatocyte growth factor 
receptor, αv integrins, and others). Different AAV serotypes express distinct capsid sequences that 
have different binding properties with each of these cell surface features. A variety of methods have 
successfully synthesized novel AAV capsids to improve tissue specificity. The insertion of the IgG 
binding domain of Protein A on the adenoviral capsid has been shown to successfully target distinct 
hematopoietic cell lines after loading the viral particles with antibodies possessing high affinity for 
cell-type specific surface markers (Ried et al., 2002). Furthermore, in vivo screens of novel AAV 
particles generated from libraries of mutated capsid sequences can identify capsid sequences with 
increased transduction efficiency in one tissue type while decreased transduction efficiency in 
others (Pulicherla et al., 2011; Yang et al., 2009). This method has been successfully used to 
identify novel liver-detargeted AAV variants with increased tropism for cardiac and skeletal muscle.  
Currently, both the National Institutes of Health (NIH) and the Juvenile Diabetes Research 
Foundation (JDRF) heavily support the generation of a novel AAV class that can target the 
endocrine pancreas with minimized liver transduction. Excitingly, the Grompe group at Oregon 
Health and Science University and the Kay group at Stanford University have made significant 
progress in developing a human pancreas-targeting, liver-detargeting AAV by screening mutated 
AAV variants in human pancreatic xenograft mouse models. In collaboration with our own lab, they 
have also successfully identified a β cell specific promoter to minimize off-target transduction of 
other islet cell types. The generation of a β cell-specific AAV would greatly enhance strategies to 
promote β cell replication in vivo through gene therapy for the treatment of diabetes.  
 
 
 
91 
 
Non-viral targeted β cell therapies in development  
 
In 2015, the discovery of a class of compounds that inhibit the dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A) has been met with great excitement in the diabetes 
research community. DYRK1A inhibits the Ca2+ dependent calcineurin-NFAT signaling pathway in 
β cells by facilitating the phosphorylation and subsequent deactivation of the NFAT transcription 
factor family. Phosphorylation of NFAT prevents nuclear transport and transcriptional activation of 
downstream cell cycle entry genes. Small molecule DYRK1A inhibitors, including harmine, 5-iodo-
tubercidin, INDY (short for INhibitor of DYrk1A), and GNF4877, increase the rate of β cell replication 
by promoting NFAT nuclear localization and activity (Dirice et al., 2016; Shen et al., 2015; Wang et 
al., 2015a). However, DYRK1A-mediated inhibition of NFAT is not exclusive to β cells. Other islet 
endocrine cell types, especially alpha cells, are significantly more responsive to DYRK1A inhibitors 
than β cells regardless of age or diabetes status (Wang et al., 2016a). Furthermore, systemic 
administration of DYRK1A inhibitor drugs could lead to undesirable hyperplasia in other organs, 
increasing the risk for tumor development.  
 
Islet-targeting nanoparticles  
To overcome the risk of non-β cell replication, nanoparticle- and aptamer-mediated drug 
carrier systems could be adapted towards targeted β cell therapies. Emerging nanotechnologies 
for pharmaceutical and biomedical imaging applications have yielded exciting results for the 
treatment and detection of many types of diseases, most notably in the field of oncology. Scientists 
have rapidly developed sophisticated nanoparticle drug carriers with specialized tissue targeting, 
drug eluting, and biodegradable properties (Singh and Lillard, 2009). These advancements have 
improved drug safety profiles of many types of anticancer agents, demonstrating many advantages 
over traditional chemotherapy regimens.  
Nanoparticles, which are commonly fabricated from lipid, polymer, silicon, or metallic 
materials, can be covalently modified with a ligand to promote binding with cell-specific surface 
receptors. To date, there have been two proof-of-principle studies demonstrating the feasibility of 
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targeting the pancreatic islets with nanoparticles. The first study was small, only using in vitro 
assays to characterize a polymer-based nanoparticle conjugated with a small peptide targeting 
EphA4 receptors, which are enriched in islet-derived capillary endothelial cells (Ghosh et al., 2012). 
The authors demonstrated that these nanoparticles preferentially targeted mouse islet capillary 
endothelial cells over skin-derived capillary endothelial cells. Furthermore, these nanoparticles 
were capable of carrying the immunosuppressant drug genistein; they also significantly decreased 
leukocyte adhesion and cytokine release in co-culture assays. However, additional in vivo studies 
are needed to demonstrate a potential application for these EphA4-targeting nanoparticles in 
delivering immunosuppressant to pancreatic islets in diabetic models. 
 The recent development of targeted iron oxide nanoparticles functionalized with 
polyethylene glycol (PEG) polymers improved live imaging of pancreatic β cells and engrafted 
insulinoma cells in mice using magnetic resonance imaging (MRI) (Zhang et al., 2013). The 
PEGylated nanoparticles were conjugated with exendin-4, a specific agonist of glucagon-like 
peptide-1 (GLP-1) receptors which are highly expressed on β cells. Although post-injection 
biodistribution analysis of the exendin-4 functionalized nanoparticles demonstrated particle 
accumulation in the liver and spleen, the nanoparticles successfully labeled pancreatic β cells and 
transplanted β cell or insulinoma grafts in vivo. This study demonstrates the feasibility of generating 
exendin-4-conjugated nanoparticle drug carriers, which could one day enable targeted drug 
delivery of small molecules to the pancreatic β cells.  
 
Developing islet targeting aptamers  
In addition to nanoparticle drug carriers, aptamer development is currently being highly 
pursued for targeted drug therapies. Aptamers are non-immunogenic single-stranded DNA or RNA 
oligonucleotides approximately 70 - 90 nucleotides in length with modified sugar-phosphate 
backbones to confer resistance to nucleases (Chen et al., 2017; Sun et al., 2014). They fold into 
tertiary structures that are highly dependent on their sequence, and can bind to molecular targets 
such as receptors or ligands with very high affinity. For example, the FDA-approved drug 
Pegaptanib is a PEGylated aptamer that binds to and inhibits vascular endothelial growth factor 
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(VEGF) for the treatment of age-related macular degeneration (Stein and Castanotto, 2017). Other 
aptamer-based therapeutics are currently undergoing preclinical and clinical studies for the 
treatment of iron disorders, cardiovascular diseases, and cancer (Catuogno and Esposito, 2017).  
Through a complex synthesis and screening process called SELEX (short for Systematic 
Evolution of Ligands by Exponential Enrichment), aptamers can be engineered to target any 
molecular target or cell population with high specificity (Maier and Levy, 2016). Briefly, an initial 
library of approximately 1015 randomized single stranded DNA (ssDNA) or RNA oligonucleotides, 
all with a constant region to allow for PCR amplification, is incubated with a molecular or cellular 
target of interest.  Unbound oligonucleotides are washed off, and target-bound oligonucleotides are 
collected. Target-bound oligonucleotides are then incubated with counter-selection targets (i.e.- 
want to keep unbound oligonucleotides because they do not possess off-target binding to counter-
selection targets), or PCR-amplified for the next round of in vitro selection with the target of interest. 
This process is continually repeated until only a few highly specific oligonucleotides remain. The 
finalized oligonucleotide aptamers can act as a therapeutic agent themselves, or can be conjugated 
either with nanoparticles for drug delivery, or with small RNA-interference (RNAi) or RNA-activation 
(RNAa) technology.  
 At the University of Miami, the Serafini group is examining the application of chimeric RNA 
aptamers for the targeted delivery of RNAi or RNAa to β cells specifically. Currently, they are testing 
the effect of aptamer-mediated delivery of an shRNA targeting CDKN1C to promote β cell 
proliferation in human islets. They have also generated aptamers that deliver small activating RNAs 
for the upregulation of XIAP and PDL1 to inhibit apoptosis and to suppress autoimmune activity, 
respectively, which could one day treat patients with Type I Diabetes.  
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